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Abstract
Alzheimer’s  disease  (AD)  is  a  neurodegenerative  disorder  that  causes  severe  and
progressive cognitive impairment. The discovery of specific mutations related to AD
supported the amyloid cascade hypothesis, which postulates that the accumulation of
the amyloid-β (Aβ) peptide triggers neuronal death and dementia. However, most
drugs that aim to prevent Aβ accumulation or tau phosphorylation have consistently
failed in clinical  trials.  This would suggest that the amyloid pathology lies down‐
stream of (an)other cellular event(s) that is/are responsible for AD pathogenesis. In this
context, several lipid alterations have been described in the brain and in peripheral
fluids of patients with AD, suggesting the involvement of lipids in the etiology of this
condition. Indeed, the central nervous system (CNS) has the highest lipid content in the
body, next to adipose tissue, and it is thought that normalization of brain membrane
lipid levels would revert AD-related pathogenic events. In this sense, novel hydroxy‐
lated derivatives of docosahexaenoic acid (DHA) such as natural resolvins or synthet‐
ic hydroxy-DHA (HDHA, DHALifort) can modulate membrane lipid composition and
show remarkable beneficial effects on AD hallmarks, such as prevention of amyloid
production  and  tau  phosphorylation,  and  cognitive  restoration  in  animal  models.
Therefore, normalization of the neuronal lipid environment by hydroxyl-DHA and/or
other lipids may constitute a promising therapy for AD treatment, memory loss and,
possibly, other types of dementia.
Keywords: Alzheimer’s disease, neurodegeneration, neuroregeneration, hydroxy-
DHA, amyloid, tau, neurite dystrophy, inflammation, brain lipids, cholesterol, sphin‐
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1. Introduction
Alzheimer’s disease (AD) is the main neurological cause of dementia, and it affects about
46 million people worldwide, mostly elderly adults. The incidence of AD increases exponen‐
tially every 5 years from 65 years of age, and it is estimated that 74.7 and 131.5 million people
will be living with AD by 2030 and 2050, respectively (World Alzheimer Report, 2015). Patients
with  AD undergo progressive  memory loss,  reduced cognitive  capacity  and eventually,
dementia. The debilitating effects of AD, especially at advanced disease stages, impose a
substantial financial burden on AD patient’s families, primarily due to the cost associated with
medical care. However, the etiology of AD still remains largely unclear and although there has
been much effort to elucidate the pathophysiological mechanisms underlying this devastat‐
ing condition over the last 20 years, the principal cause remains unknown, representing an
important unmet clinical need. Therefore, AD is undoubtedly one of today’s most challeng‐
ing global public health problems, and there is a pressing need to develop novel therapeutic
agents to prevent and treat this disease.
The neuropathological hallmarks of AD include the formation of extracellular senile plaques
due to the aggregation of amyloid-β (Aβ; normally associated with local inflammation and
dystrophy/swelling of neurites), the formation of intracellular neurofibrillary tangles of hyper-
phosphorylated tau protein, as well as a loss of synaptic connections and neuronal degenera‐
tion [1]. Clinically, AD can be classified into two categories: familial AD (FAD, also known as
early-onset AD) and sporadic AD (SAD, also known as late-onset AD). FAD generally accounts
for <1% of the total AD cases, and they correspond to a disease variant with onset prior to
65 years of age [2]. This familial form of AD is inherited in an autosomal dominant pattern,
and it is caused by mutations in three genes involved in Aβ generation: the amyloid precursor
protein (APP), presenilin 1 (PS1) and presenilin 2 (PS2) [3]. In contrast to FAD, no single gene
mutation has been found to be directly responsible for the onset and pathogenesis of SAD [4].
For the late-onset cases, the principal risk factors are ageing and the apolipoprotein E (ApoE)
allele ε4 (see Section 3.1.).
The identification of clinical mutations in APP and presenilins in association with FAD has
contributed to our understanding of AD pathogenesis. APP is a transmembrane protein that
undergoes primary enzymatic cleavage by an α- or β-secretase in its extracellular (or
intraluminal) domain, as well as secondary cleavage by a γ-secretase within the transmem‐
brane region (Figure 1). The metalloproteases ADAM10 and/or ADAM17 appear to be
responsible for this α-secretase activity and the aspartyl protease BACE-1 (beta-site APP
cleaving enzyme 1) corresponds to the β-secretase activity, whereas γ-secretase is an aspartyl
proteolytic complex containing four subunits (PS1 or 2, nicastrin, APH1, and PEN-2) [5]. APP
cleavage may be produced by β- and γ-secretases in a pathway known as the amyloidogen‐
ic route of APP. First, APP β-cleavage produces soluble APP-β (sAPPβ) and a transmem‐
brane C-terminal fragment known as β-CTF or C99. The latter then undergoes γ-secretase
cleavage to generate the APP intracellular domain (AICD) and the Aβ peptide, preferential‐
ly the Aβ40 and 42 isoforms. Alternatively, APP may be cleaved by α- and γ-secretases in a
pathway known as the non-amyloidogenic route of APP where α-secretase cleaves APP right
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in the middle of the Aβ sequence (Figure 1) to generate soluble APPα (sAPPα) and a
transmembrane C-terminal fragment known as α-CTF or C83. The latter undergoes further
γ-cleavage to produce AICD and p3 (also known as Aβ17–40/42). In this context, it has been
widely reported that FAD mutations induce alterations in APP processing that increased the
cellular production of Aβ and augment the Aβ 42/40 ratio. Since mutations in both APP and
presenilins are the major causal factors in FAD etiology, altered APP metabolism was assumed
to be the principal cause triggering AD, leading to the formulation of the amyloid cascade
hypothesis more than 20 years ago. Finally, it is notable that all these participants in APP
metabolism, APP and secretases, are membrane-associated proteins influenced by the
composition and structure of cell membrane lipids that in turn modulate APP metabolism [6].
Figure 1. APP processing by secretases. In the non-amyloidogenic pathway, APP is first cleaved by α-secretase at a
sequence of amino acids within the Aβ peptide, releasing the sAPPα ectodomain. Further processing of the resulting
membrane-associated C-terminal C83 fragment (α-CTF) by γ-secretase leads to the release of the p3 fragment and the
APP intracellular domain (AICD). This processing takes place preferentially at the plasma membrane. Conversely, the
amyloidogenic pathway is initiated when β-secretase cleaves APP at the amino terminus of the Aβ peptide to release
the sAPPβ ectodomain. Further processing of the resulting membrane-associated C-terminal C99 fragment (β-CTF) by
γ-secretase releases the Aβ peptide and AICD. This processing normally takes place in acidic cellular compartments
like late endosomes. The Aβ peptide produced is normally 40 or 42 amino acids long (Aβ40 or 42) and the Aβ42/40
ratio increases in AD.
2. Historical perspective on the pathophysiology of Alzheimer’s disease
For more than 20 years, the accumulation of the Aβ peptide has been considered to be the main
cellular/molecular event that triggers AD-related neurodegeneration. Amyloid plaques were
first thought to cause AD pathogenesis, and more recently, Aβ-soluble oligomers have gained
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more attention as key players in AD etiology [7]. Regardless of the form of amyloid, the
amyloid cascade hypothesis postulates that Aβ accumulation in the brain is the major upstream
event in AD pathophysiology, whereas other neuropathological features are a result of this
primary amyloid pathology, including the formation of neurofibrillary tangles, neuroinflam‐
mation, synaptic failure, and eventually neural death [8, 9].
According to the amyloid cascade hypothesis, enhanced amyloidogenic activity of secretases
and/or reduced clearance of the Aβ peptide may trigger Aβ accumulation. As a result, the
secretases involved in Aβ generation have been extensively targeted by the pharmaceutical
industry to develop new compounds to treat AD [10]. In particular, the Aβ42/40 ratio may
increase due to FAD mutations and this increase enhances oligomer formation, which may in
turn impair synaptic function and provoke neuronal degeneration [7]. At the same time,
secreted Aβ42 forms primary extracellular Aβ deposits in the brain parenchyma, first as diffuse
plaques and later as insoluble fibrillary plaques. A concomitant local inflammatory response
develops around these amyloid deposits (involving microglial and astroglial activation),
coupled to synaptic spine loss and neurite dystrophy (neuritic pathology) [11, 12]. Over time,
these events result in oxidative stress and altered ion homeostasis. Neurofibrillary tangles
appear as a consequence of the altered kinase and phosphatase activities that cause tau protein
hyperphosphorylation, and likely its subsequent dysfunction in axonal transport, as well as
neurite dystrophy [13, 14]. Finally, the cascade ends with extensive synaptic and neuronal
dysfunction, which precedes the well-characterized neuronal death associated with the Aβ
and tau pathologies [7]. It is this neuronal degeneration that is responsible for memory loss
and dementia in patients with AD.
Amyloid burden in the brain parenchyma is closely associated with tau hyperphosphorylation,
axonal dystrophy and inflammatory reaction around amyloid plaques (Figure 2). Both,
inflammation and axonal dystrophy can promote neuronal degeneration [15, 16]. However, it
is still largely unknown which of these events (amyloid, inflammation, or neurite dystrophy)
appear first during disease development and how these three events are connected. The
amyloid cascade hypothesis postulates that amyloid accumulation, first intracellular and then
extracellular, leads to the generation of amyloid plaques. Given the close relationship between
Aβ plaque number and size with the surrounding dystrophies and gliosis, these two latter
events were proposed to progress in conjunction with Aβ plaque formation. However,
evidence is now accumulating against the amyloid cascade hypothesis. On the one hand,
therapeutic approaches focused on combating amyloid pathology have generally failed to
prevent AD progression in clinical trials (see Section 4, [17, 18]), while on the other hand,
transgenic AD animal models, mostly created by incorporating human mutated APP and/or
PS1 into the animal genome, do not recapitulate all the neuropathological features of AD, and
not even the large scale neuronal death that occurs during this pathology [19]. Moreover, the
alterations to membrane lipids in neurons of patients with AD suggest that the changes to lipid
bilayer could be the first event in the amyloid cascade and related pathways [6]. Indeed, the
normalization of membrane lipids is associated with cognitive restoration (see Section 5.2).
Accordingly, the amyloid pathology may not actually be the first initial event driving the
events that provoke neuronal degeneration.
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Figure 2. Dystrophic neurites surrounding β-amyloid plaques in AD patient’s brain. (a–c) Double-labeling immuno‐
fuorescence and confocal microscopy to mitochondrial porin (a; green) and β-amyloid plaques (b; red). Porin immu‐
nostaining revealed mitochondrial enrichment in dystrophic neurites surrounding amyloid plaques (c). (d–f) Double-
labeling immunofluorescence and confocal microscopy to mitochondrial porin (d; red), and phosphorylated tau
(pThr181) (b; green) show co-segregation of porin and hyperphosphorylated tau in dystrophic neurites (long arrow in
f). (g–i) Double-labeling immunofuorescence and confocal microscopy to lysosomal associated protein 1 (LAMP-1) (a;
green) and mitochondrial porin (b; red). LAMP-1 and porin co-localize in a subset of cellular processes (c; arrowheads)
suggesting engulfment of mitochondria into matured autophagic vesicles and participation of lysosomes in its degra‐
dation in distrophic neurites. β-Amyloid is stained in blue. Bar 10 μm (a–c and d–f), and 20 μm (g–i). Adapted from
[12] with permission of Springer.
It also appears that axon swelling or dystrophy can precede extracellular amyloid deposition
in certain animal models, in which autophagic vesicles with all the necessary enzymatic
machinery to produce the Aβ peptide are evident [20–23]. In this sense, dystrophic axons have
been proposed to be an intracellular source of secreted Aβ that would seed extracellular
amyloid plaques. Protein deposits containing APP fragments can be seen in the brain
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parenchyma of aged wild-type mice, originating from axonal varicosities, further supporting
this hypothesis. These data suggest that axonal dystrophy occurs first, leading thereafter to
extracellular amyloid deposition in the early stages of the disease. In fact, it has been proposed
that neurite dystrophy could reflect a conserved neuroprotective strategy to overcome the age-
related accumulation of misfolded proteins, which in turn may represent a molecular
mechanism of Aβ plaque deposition that potentially underlies the shift from normal to
pathological aging [24, 25]. Nevertheless, Aβ alone may promote axonal atrophy through its
interactions with the p75 neurotrophin receptor (p75NTR) in axon membranes [26]. Together,
the evidence suggests that dystrophy and extracellular Aβ deposition are involved in a
positive feedback loop whereby axon dystrophy is a source of extracellular Aβ, and the latter
promotes axonal atrophy.
In terms of neuroinflammation, it is widely accepted that Aβ deposition alone might be
sufficient to induce an inflammatory reaction that subsequently contributes to neuronal death
and cognitive decline in AD [15]. However, this fact does not necessarily imply that Aβ plaque
formation precedes microglial activation in AD. During normal aging, microglial activation
aims to clear the misfolded proteins contained in fragmented neurites and aggregated into
senile plaques. Interestingly, during AD-related pathological ageing, microglia cells recruited
around plaques phagocytose Aβ and this could constitute part of the microglial mechanism
to clear misfolded proteins, also during normal ageing [25]. Thus, in a scenario characterized
by age-related chronic inflammation, microglia would be highly responsive to further
activation which would drive their differentiation toward a classic phenotype characterized
by pro-inflammatory cytokine secretion, in turn impairing axon trafficking, promoting Aβ
accumulation and cell death [25, 27]. However, this putative role for AD-associated neuroin‐
flammation is not supported by evidence showing that the inflammatory response is not
neurotoxic and, indeed, it is even neuroprotective in a transgenic mouse model of AD [28]. In
fact, from early in the amyloid pathology, alternative neuroprotective microglia are activated
around amyloid plaques supporting neuronal survival, and this alternative phenotype is also
present during animal ageing. By contrast, the classic microglial phenotype that is character‐
ized by cytotoxic cytokine secretion only appears at advanced ages, associated with the
presence of soluble Aβ oligomers and neuronal loss [27, 28]. Thus, these evidences show that
alternative neuroprotective microglia may be present at advanced ages and coexist with classic
microglial activation. In summary, although it is widely accepted that neuroinflammation
promotes neuronal degeneration, it remains unclear how brain inflammation participates in
the shift from normal to pathological ageing.
Hence, determining whether amyloid pathology is the first event in the pathway to AD-
associated neuronal degeneration and dementia appears to be a particularly relevant issue,
especially after the repeated fiascos in clinical trials of drugs targeting Aβ and related molec‐
ular entities. There is a close relationship among Aβ, inflammatory and neurite pathologies in
AD because they all appear at early stages of the disease and all three are involved in neuronal
death. In the present chapter, we will review how these neuropathological hallmarks are
related to AD-associated membrane lipid alterations, as there can now be no shadow of doubt
that brain lipids and the pathways they are involved in influence the pathophysiology of AD.
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3. Brain lipid alterations in Alzheimer’s disease
3.1. Cholesterol and sphingolipid homeostasis in AD
The amyloid cascade hypothesis was postulated because FAD mutations cause Alzheimer’s
disease, and they induce abnormal APP processing that leads to the well-characterized
amyloid pathology [9]. Since the pathological hallmarks are exactly the same for both FAD
and SAD, the same cascade of neuropathological events is thought to occur in both these
disease variants. However, in addition to the influence of FAD clinical mutations on APP
metabolism, these mutations may also have additional effects on other signaling cascades. In
fact, presenilins (PSs) are the catalytic center of the γ-secretase complex, which cleaves more
than 60 type I membrane proteins (one type of single transmembrane spanning region in
integral proteins) [29, 30]. More than 160 clinical mutations have been described for PS1 and
most of those that were studied induce loss of function of γ-secretase activity [31, 32]. These
mutations may exert additional effects on cellular signaling as a consequence of the altered
processing of certain membrane proteins that could influence lipid cellular homeostasis.
Interestingly, γ-secretase loss of function induced by the ablation of PSs or by transgenic
expression of PS1 mutants provoked a severe imbalance in the cholesterol content of the plasma
membrane and intracellular membranes [33, 34]. In this sense, PS ablation increased the overall
levels of cholesterol and sphingomyelin (SM) in cells, whereas the local concentration of
cholesterol at the plasma membrane was dramatically reduced, resulting in the intracellular
accumulation of cholesterol and cholesterol-rich membrane domains, such as lipid rafts [33,
34]. These observations demonstrate the impact of γ-secretase loss of function on the cell
membrane lipid composition.
In the human brain, cholesterol is mainly transported in lipoprotein particles that predomi‐
nantly contain ApoE. Interestingly, ApoE has been identified as a risk factor for SAD suggest‐
ing that altered cholesterol transport might also be related to the pathogenesis of late-onset
AD [35]. The human ApoE protein is comprised of 299 amino acids and it has three isoforms,
namely ApoE2, ApoE3, and ApoE4. The differences between these three isoforms lie in the
amino acid residues at positions 112 and 158: ApoE2 (Cys112, Cys158), ApoE3 (Cys112,
Arg158), and ApoE4 (Arg112, Arg158). In particular, subjects carrying the ApoE4 allele have
a 3- to 4-fold higher risk of developing AD than those who do not carry this allele. Furthermore,
ApoE4 was observed to exhibit a gene dose–effect, such that individuals who carry two copies
of this allele have an even higher risk of suffering AD and an earlier age of onset. The effects
of the ApoE4 isoform on AD risk are maximal between the ages of 60 and 70 years old, ApoE4
allele being present in more than 50% of all AD cases. Conversely, ApoE2 carriers appear to
be somewhat protected from AD compared with ApoE3 carriers [36]. In this context, the ApoE4
isoform is less efficient in promoting cholesterol flux in neurons and astrocytes, and it also
compromises cell uptake of cholesterol-containing lipoproteins compared with the other ApoE
isoforms [37]. Furthermore, individuals carrying the ApoE4 allele accumulate less ApoE
lipoprotein in the brain than non-ApoE4 carriers [38]. Hence, the expression of ApoE4 in SAD
cases appears to alter cholesterol homeostasis in neurons in a similar way as that induced by
γ-secretase loss-of-function in PS1-deficient cells and transgenic models of AD harboring
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clinical PS1 mutations [33, 34]. In such AD models, the loss of γ-secretase activity leads to
impaired uptake of lipoproteins from the extracellular media due to the poor internalization
of ApoE receptors like the LDLR (low-density lipoprotein receptor) [34]. In AD patients with
the ApoE4 allele, cholesterol uptake would be impaired due to the lower affinity of ApoE4 to
bind neuronal lipoprotein receptors, and to the lower concentration of circulating ApoE than
in individuals carrying the ApoE2 or ApoE3 alleles [38, 39]. In any case, poorer membrane
incorporation of neuronal cholesterol leads to increased de novo cholesterol synthesis and an
altered neuronal distribution. Thus, altered cholesterol homeostasis is a key aspect of AD
pathogenesis and alterations to cholesterol may represent a meeting point in the pathogenesis
of FAD and SAD, driving the same neuropathological events in both disease variants, such as
increased amyloidogenic APP processing.
The central nervous system (CNS) contains around 25% of the cholesterol in the body and
evidence is accumulating that cholesterol homeostasis is indeed associated with AD patho‐
genesis. High cholesterol and high-density lipoprotein (HDL) in blood plasma are correlated
with Aβ load in the brains of patients with AD [40, 41] and that increased cholesterol levels
are associated with the incidence of AD [42, 43]. Furthermore, high or low cholesterol levels
have often been related to enhanced or diminished Aβ production, respectively, in cell and
animal models of AD, although these results are a little controversial [42, 44, 45]. What is more,
lipidomic studies have shown that levels of cholesterol, certain cholesterol esters, and certain
SM species are upregulated in the brain of patients with AD. This correlation is particularly
strong in the case of patients with AD harboring the ApoE4 allele, although some contradictory
results have also been reported in this respect [46–49]. Finally, altered cholesterol distribution
and transport have been causally linked to neurodegenerative diseases in addition to AD, such
as Huntington’s and Niemann–Pick Type C diseases [44].
Cholesterol is an essential structural component of cell membranes and one of the major
components of the functional membrane microdomains known as lipid rafts, together with
sphingolipids such as SM and gangliosides. These microdomains are highly ordered mem‐
brane structures that serve as platforms for cell signaling, ligand-receptor binding, protein
sorting, and other activities in the cell. Interestingly, amyloidogenic APP processing and Aβ
aggregation have been proposed to take place in lipid rafts [50]. In fact, the activities of both
BACE-1 and γ-secretase are enhanced in this type of membrane microdomains [51, 52]. In this
context, compelling evidence supports the involvement of cholesterol and sphingolipids in the
amyloidogenic processing of APP. On the one hand, membrane enrichment of these lipids
could alter the biophysical properties of the lipid bilayer, affecting secretase activity in a
manner that leads to the production of the longer pathogenic Aβ peptides instead of the shorter
p3 peptide [53] (see Figure 1). On the other hand, cholesterol and SM storage disorders impair
intracellular trafficking of APP, resulting in the accumulation of APP, APP-CTFs, and Aβ in
autophagic vesicles of the endolysosomal pathway [54, 55]. Accordingly, impaired distribution
of cholesterol and SM is accompanied by the downregulation of proteins involved in endoso‐
mal redistribution and fusion to the plasma membrane (SNAREs and RABs) in PS1-deficient
cells [33]. These evidences suggest that dysfunctional vesicular trafficking between the plasma
membrane and intracellular compartments may be caused by membrane lipid alterations that
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lead to the neuritic pathology and altered APP processing in FAD transgenic models [33, 56].
Additional studies have also linked shingolipid lysosomal accumulation to autophagic
dysfunction and dystrophic neurite formation in AD [55, 57]. Such results indicate that cellular
accumulation of sphingolipids could induce key cytopathological changes characteristic of
AD, such as alterations to the autophagic/lysosomal system, increased generation of Aβ and
accumulation of APP-CTFs in autophagic vesicles at dystrophic neurites, as occurs in an age-
dependent manner in transgenic mouse models of AD [58]. Interestingly, a cholesterol-
enriched diet in healthy mice also leads to insulin-like growth factor 1 (IGF1) impairment and
insulin-mediated pro-survival signaling, which in turn promotes tau hyperphosphorylation
in neurons [59]. Together, this evidence suggests that altered cholesterol/sphingolipid
homeostasis may promote the neurite pathology, tau hyperphosphorylation, and amyloido‐
genic APP processing in AD.
Nevertheless, it cannot be ruled out that AD-related membrane lipid alterations can also
potentiate the neurotoxicity of the Aβ oligomers in AD patient’s brains. In fact, lipid rafts may
serve as a platform for the cellular interactions with soluble Aβ oligomers, in turn promoting
tau hyperphosphorylation and inhibiting synaptic plasticity by hindering LTP (long-term
potentiation) in the brain [60, 61]. Moreover, raft-associated lipids such as cholesterol, SM, and
the GM1 ganglioside revert the fibrillar Aβ into soluble oligomers, such that altered cellular
lipid homeostasis may actually potentiate the severity of the amyloid pathology in AD [62].
3.2. Polyunsaturated fatty acids in AD
Polyunsaturated fatty acids (PUFAs) are those fatty acids that contain more than one double
bond in their backbone. They are abundant in cell membranes, and they are mainly incorpo‐
rated into membrane phospholipids. The carbon next to the carboxyl group is known as the
α carbon, the next one is the β carbon, and so forth, until the final carbon called the ω carbon.
Thus, ω-3 fatty acids have the first double bond between the third and fourth C atoms from
the ω carbon. For instance, 22:6 ω-3 or 22:6 n-3 (docosahexaenoic acid, DHA) indicates a 22-
carbon chain with six double bonds and with the first double bond between the third and
fourth carbons from the CH3 end. The physiological properties of unsaturated fatty acids
largely depend on the position of the first unsaturation relative to the end position. The
essential fatty acids α-linolenic acid (ALA, 18:3 ω-3) and linoleic acid (LA, 18:2 ω-6) must be
incorporated through the diet, and they are the starting point for the synthesis of longer and
more unsaturated PUFAs such as arachidonic acid (ARA, 20:4 ω-6), eicosapentaenoic acid
(EPA, 20:5 ω-3), and DHA (22:6 ω-3). However, conversion of ALA to longer PUFAs in humans
is very inefficient and therefore, these long PUFAs are normally incorporated through the diet,
particularly through fish intake [63].
The membranes of the cells in the brain are rich in ω-3 PUFAs such as DHA and EPA. Since
AD is a cognitive disorder and DHA is involved in normal cognitive development, the DHA
levels in the AD brain have been analyzed extensively. As a result, it is widely accepted that
in the human brain AD courses with diminished DHA levels, although a number of discrep‐
ancies in this respect have also been observed [64]. These discrepancies may reflect the brain
region studied as the neurodegeneration associated with AD does not affect all brain areas
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homogeneously. In the hippocampus, one of the regions primarily affected in AD, decreased
DHA levels are associated with reduced levels of PE (phosphatidylethanolamine) or PE
plasmalogens [65–69], supporting a relationship between lower DHA levels and cognitive
decline in AD. Moreover, there is significant experimental evidence in animal models that
hippocampal DHA deficiency or enrichment is associated with reduced or increased learning
memory abilities, respectively [70]. At the cellular level, exposure to ω-3 PUFAs enhances
synaptic plasticity by increasing LTP and synaptic protein expression, in turn leading to
increased dendritic spine density and hippocampal neurogenesis. In addition, ω-3 PUFAs have
antioxidant, anti-inflammatory, and anti-apoptotic effects, thereby promoting neuronal
survival during normal ageing and in AD. On the other hand, PUFA deficits are related to
enhanced amyloidogenic APP processing and cell susceptibility to Aβ neurotoxicity, particu‐
larly as ω-3 PUFA deficiency downregulates neuroprotective signaling (e.g., ERK signaling).
Therefore, PUFA deficits may enhance neuron degeneration and cognitive impairment in AD
[71].
It still remains largely unclear how ω-3 PUFAs exert their cellular functions and consequently,
what signaling cascades are impaired in the brain due to their deficiency. Such ω-3 PUFAs
maintain the structural functionality of neural cell membranes. Indeed, in consonance with the
reduced levels of DHA in the human AD brain, lipid rafts obtained from AD brain cortex also
exhibited significantly less DHA than age-matched controls [72]. Interestingly, the biophysical
and structural properties of PE and DHA in membranes are opposed to those of cholesterol
and SM. Thus, these abnormalities in lipid raft composition may provoke strong modifications
to the membrane structure of neurons such as alteration of membrane viscosity, rigidity and
thickness, lateral lipid packing, lipid order, and other parameters, which could in turn be
relevant to secretase activity and the production of Aβ [73]. Accordingly, decreased PUFA
levels in lipid rafts would be coupled to enriched cholesterol and sphingolipids, thereby
promoting the detrimental effects on neurons including the neurite dystrophy, tau hyper‐
phosphorylation, and amyloidogenic APP processing that drives neuronal degeneration (see
Section 3.1.).
Alternatively, DHA may be released from phospholipids due to the activity of PLA2 (phos‐
pholipase A2), acting as a signaling molecule, and DHA can be hydroxylated to produce
several secondary bioactive lipids such as resolvins (RVs) and protectins. DHA hydroxylation
is mediated through lipoxygenase-15 (LOX-15) or acetylated cyclooxygenase-2 (COX-2) [63].
Compounds derived from DHA are classified as D-series RVs or protectins, while those formed
from EPA are designated as E-series RVs. DHA can be hydroxylated on carbon 17 by 15-LOX
or acetylated COX-2, leading to stereoselective formation of 17S- or 17R-hydroxy-DHA (17-
HDHA), respectively. These derivatives may be further hydroxylated to give rise to trihydroxy
derivatives such as the D1, D2, D3, and D4 17-(S/R)-RVs (D-series RVs), and the dihydroxy 17-
(R)- and 17(S)-protectin, the latter also known as neuroprotectin D1 (NPD1). EPA can be
stereoselectively hydroxylated to 18-(S/R)-hydroxy-EPA (18-HEPA) by cytochrome P450 or
acetylated COX-2, which is further processed to form E1, E2 and E3 18-(S/R)-RVs (E-series RVs:
Figure 3). Both, 17-HDHA and 18-HEPA serve as markers for RVs and protectins, and
remarkably, their presence in blood is directly related to the intake of ω-3 PUFAs in animal
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models [74]. In addition, these PUFA derivatives are thought to exert their biological function
by mechanisms that go beyond the simple regulation of lipid membrane composition and
structure. In fact, non-esterified DHA, RVs and protectins may bind to different fatty acid (FA)
receptors such as the retinoid X receptor (RXR), G protein-coupled receptors (GPCRs),
peroxisome proliferator-activated receptors (PPARs), and fatty-acid binding proteins (FABPs).
Although the exact signaling cascade mediated by many of these proteins has not been
identified, the mechanism of action of DHA or HDHA derivatives like NPD1 has been
proposed to involve PPARγ activation. Indeed, NPD1 is known to promote PPARγ activation
more intensely than DHA and as such, the neuroprotective effects of DHA may be mediated
by NPD1 and/or other DHA-derived hydroxylated bioactive derivatives in the brain [75, 76].
Figure 3. Chemical structure of specialized pro-resolving mediators derived from DHA and EPA ω-3 fatty acids. DHA
(docosahexaenoic acid) and EPA (eicosapentaenoic acid) may be released from phospholipids through PLA2 (phos‐
pholipase A2) activity and converted into bioactive hydroxylated fatty acids with potent anti-inflammatory properties,
known as resolvins and protectins. This conversion may be mediated by several enzymes, including lipoxygenase-15
(LOX-15), acetylated cyclooxigenase-2 (COX-2), and cytochrome P450. Compounds derived from DHA are classified as
D-series resolvins (RVs: left panel), while those formed from EPA are designated as E-series resolvins (right panel).
Although resolvins normally includes trihydroxy fatty acids, DHA can be also transformed into dihydroxylated com‐
pounds denominated as protectins. Within this group, neuroprotectin D1 (NPD1: see left panel) is the best studied
DHA-derived hydroxylated compound in terms of AD therapy, and it displays anti-inflammatory, anti-apoptotic, and
anti-amyloidogenic properties.
The balance between ω-6 to ω-3 intake has a strong impact on brain health. In Western diets,
this ratio is about 10–20:1, while in other cultures and also historically, this ratio has been as
low as 1–2:1. Total fat intake as well as the ω-6 to ω-3 ratio in Western diets has increased
significantly since the Industrial Revolution, indicating that Western diets are deficient in ω-3
PUFAs [77]. Epidemiological studies, including correlational studies and migration studies,
suggest a protective effect against AD of ω-3 PUFAs and fish oil (an important source of ω-3
PUFAs), such that the role of nutrition in preventing AD arouses increasing hope, particularly
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with reference to ω-3 PUFA dietary intake. One recent meta-analysis reviewed a total of six
cohort studies performed in the USA and Europe to address how dietary intake of long-chain
ω-3 PUFAs or fish correlates with the incidence of dementia and AD [78]. This meta-analysis
found a significant lower risk of AD associated with high fish intake. Such an association was
most pronounced when the follow-up period was at least five years and fish intake was 500 g
or more per week, such that fish consumption is inversely correlated with AD incidence in a
temporal and quantitative manner. A dose–response meta-analysis also showed that for every
100 g per week dietary fish intake the risk of AD falls 11%. This neuroprotective effect of fish
intake was mainly attributed to its high long-chain ω-3 PUFA content, particularly DHA [79].
Interestingly, the same meta-analysis also revealed that dietary intake of ω-3 PUFAs alone (not
linked to fish consumption) did not lower the risk of dementia or AD. Moreover, an earlier
randomized trial reached the same conclusions in patients with mild-to-moderate AD who
were administered DHA [80]. Nevertheless, most of the individual studies evaluating the
relationships between ω-3 PUFA intake and AD risk suggest there is a potential protective
effect of these long ω-3 PUFAs on the incidence of AD, although no significant statistical
differences were reached in the pooled analysis.
The discrepancies between fish and ω-3 PUFA consumption in relation to AD incidence may
be explained by different factors in terms of the dietary composition or socioeconomic status
of the individual. In this context, dietary intake of long-chain ω-3 PUFAs may also be accom‐
panied by the intake of other saturated fats, which would attenuate the neuroprotective effect
of ω-3 PUFAs. Alternatively, fish is also a good source of vitamins, essential amino acids and
other nutrients, which could in turn be responsible for the beneficial effect attributed to fish
in AD prevention. The fact that DHA is converted into bioactive derivatives that mediate its
beneficial effects in CNS cannot be overlooked. In this context, the neuroprotective effect of
fish intake could be also attributed to PUFA derivatives present in fish, such as hydroxylated
forms of PUFAs or PUFA forms easily transformable into bioactive derivatives similar to NPD1
[81]. In fact, fish oil consumption has recently been related to increased levels of total DHA
and NPD1-like derivatives in the mouse brain, without any modification of free (unesterified)
DHA levels [82]. Hence, fish oil intake promotes elevated levels of NPD1 without affecting
basal levels of free DHA in the brain. These data bring to light a central role for ω-3 PUFA
hydroxylated bioactive derivatives in the prevention and treatment of AD (see Section 5.2.).
3.3. Specific lipid alterations as potential biomarkers in AD
Modern lipidomic analysis allows a comprehensive atlas to be built up of all the lipid altera‐
tions existing in the AD brain. Current laboratory techniques, such as ultra/high pressure
liquid chromatography (U/HPLC) and gas chromatography (GC) coupled to mass spectrom‐
etry (MS) allow the vast majority of lipids in cells and animal tissues to be studied. Since the
brain is the most lipid-enriched organ in the human body, after adipose tissue, alterations in
lipid composition might be involved in many neurological disorders, including AD [44]. An
in-depth lipidomic analysis performed in the postmortem brain of patients with AD showed
heterogeneous changes in lipid metabolism in AD-affected patients [47]. As expected, the
cerebellum lipid profile was largely unaffected whereas significant lipid changes were
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observed in the prefrontal and entorhinal cortex of AD brains when compared with age-
matched controls. These changes demonstrate that lipid alterations are restricted to AD-
affected brain regions (principally the cortex and hippocampus) and that they are not present
in unaffected regions like the cerebellum. Interestingly, the prefrontal cortex displays more
severe lipid alterations, with a decrease in PE, LPC (lyso-phosphatidylcholine), and sulfatides,
together with elevated levels of ceramides (including glucosyl- and galactosyl-ceramides, Cer)
and DAG (diacylglycerol). By contrast, in the entorhinal cortex, significant increases are only
evident in LBPA (lysobiphosphatidic acid), SM, ganglioside GM3, and cholesterol esters
(ChoE). In addition, polyunsaturated PE 40:6, 38:6, and 38:4 species were markedly downre‐
gulated in the prefrontal cortex, whereas there was a general decrease in long-chain fatty acids
(≥40C) and a corresponding increase in short-chain fatty acids (≤34C) that is compatible with
the lower levels of PE carrying DHA in the brain of patients with AD. Unexpectedly, the
entorhinal cortex displays more species of the polyunsaturated lipid pools in PC (phosphati‐
dylcholine) and PE. The different lipid alterations between these two brain regions may reflect
different aspects or stages of AD pathophysiology, since the entorhinal cortex is known to be
affected earlier and more severely than neocortical areas [83].
AD progresses from a pre-symptomatic stage to mild cognitive impairment (MCI), mild AD
and to severe AD with a gradual deterioration in cognitive abilities. Unfortunately, the clinical
manifestation of the disease is preceded by a long prodromal phase, during which neuropa‐
thological lesions arise, including neuron death. For this reason, clinical diagnosis of AD is
unreliable, particularly at early disease stages. Hence, there is a strong need to find peripheral
biomarkers to reliably diagnose AD early, thereby enabling early treatment and better
therapeutic efficacy. Most approaches to fluid-based biomarker discovery have focused on
Aβ42, total tau and phosphorylated tau in cerebrospinal fluid (CSF). Although these are useful
to distinguish symptomatic patients from normal controls or other dementias, these CSF
biomarkers lack predictive value in preclinical patients, and they are only useful to confirm
the clinical diagnosis [84]. Thus, given the brain lipid alterations in AD, lipidomic analysis of
lipid derivatives in biological fluids may represent a reliable way to identify non-invasive
biomarkers for early AD diagnosis [85].
Of the lipid changes reported in the CSF, plasma, and serum of patients with AD, many do
not necessarily correlate with those described previously in the CNS [6]. For instance, free
cholesterol and ChoE were reported to be downregulated in the CSF although they are
increased in the brain of patients with AD [86] (see Section 3.1.). However, six different long-
chain ChoE species in plasma allowed patients with AD to be accurately discriminated from
healthy controls (ChoE 32:0, 34:0, 34:6, 32:4, 33:6, and 40:4). These metabolites accumulated
more strongly in healthy controls than in MCI, and in MCI than in AD, such that they were
proposed as potential biomarkers for early AD diagnosis [87]. Total PC levels and specific PC
species have also been proposed as reliable biomarkers, with diminished PC levels in the CSF
of patients with AD accompanied by lowered LPC and increased PC hydrolytic products such
as glycerophosphocholine and phosphocholine, suggesting that PC breakdown might be
enhanced in AD pathogenesis [88]. Notably, a set of 10 PC metabolites was specifically depleted
in the plasma of healthy individuals who later suffered phenoconversion towards MCI/AD.
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These subjects were diagnosed as AD during a 5-year follow-up even though they displayed
no cognitive impairment at entry. The PC species identified were diacyl PC 36:6, 38:0, 38:6,
40:1, 40:2, 40:6, PC acyl-alkyl 40:6, and LPC 18:2, as well as the acylcarnitines (ACs) propionyl
AC (C3), and C16:1-OH [89]. It is noteworthy that control subjects (not previously diagnosed
with AD) did not display any of these modifications, while already diagnosed patients with
AD also showed decreased levels of these PC species. Moreover, downregulation of this panel
of lipids predicted phenoconversion from healthy to MCI/AD within a 2–3 year time frame
with 90% accuracy [89]. These data were supported by independent studies showing decreased
levels of PC 38:4, 38:6, and 40:6 in the plasma or serum of AD subjects [86, 90]. In addition, a
variety of peripheral lipid changes were also reported that might potentially be useful for early
AD diagnosis, such as lower levels of SM and increased levels of Cers in the plasma or serum
of patients with AD. In particular, there were significantly fewer SM species containing long
chains (e.g., 22 and 24 carbon atom acyl chains) in AD subjects [86, 91]. In parallel, increased
Cer levels were reported in the plasma of patients with AD [91, 92]. SM can be metabolized
into Cers, second messengers that regulate cellular differentiation, proliferation and apoptosis.
Upregulated levels of Cers were concomitant with significant reductions in SM in the plasma
of patients with AD. A correlation between the decrease in SM and the increase in Cers was
particularly robust in the ratios of SM and Cer species with identical fatty acyl chains. Cer
alterations were particularly evident in mild-to-moderate stages of AD [91]. Moreover, it is
noteworthy that upregulated Cer levels were significantly correlated with the onset of memory
impairment, supporting the role of Cers as potential AD biomarkers [92].
In conclusion, a wide range of peripheral fluid changes have been described that could be used
as biomarkers for early AD diagnosis. However, many of the clinical studies involved are cross-
sectional in nature and some of them do not reveal reliable biomarkers to test disease pro‐
gression. Nevertheless, longitudinal studies with several years of follow-up do identify
promising biomarkers for early AD diagnosis that reliably predict cognitive impairment and
the onset of AD.
4. Prevention and treatment of Alzheimer’s disease
The main risk factors for dementia are age and genetics (see more information about AD risk
factors at http://www.alz.org/alzheimers_disease_causes_risk_factors.asp), although other
risk factors may also influence the onset of dementia. For instance, since the brain is nourished
by a rich network of blood vessels, cardiovascular alterations are considered a risk factor for
neurological disorders. In fact, vascular dementia is linked to morphological changes to blood
vessels which are in turn present in other types of dementia like AD. Indeed, a healthy
cardiovascular system is frequently linked to brain protection [93]. In this context, the control
of blood cholesterol levels, blood pressure, and body weight is recommended to maintain good
brain health. In fact, high-fat diets and sedentary lifestyles are becoming major concerns in
terms of their contribution to the high incidence of dementia in Western society, whereas
regular physical exercise and heart-healthy diets are also good habits to lower the risk of
dementia [35].
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Only two types of drugs are currently available to treat Alzheimer’s disease: acetylcholines‐
terase inhibitors (often shortened to just “cholinesterase inhibitors”) and NMDA receptor
antagonists. Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) bind to and
reversibly inactivate cholinesterases, inhibiting acetylcholine hydrolysis. Such inhibition
results in increased acetylcholine concentrations at cholinergic synapses and indeed, AD
involves a substantial loss of cholinergic neurons in the neocortex and hippocampus, which
in turn contributes to the AD symptomatology and to memory impairment in particular.
Therefore, increased levels of acetylcholine are thought to protect against the death of
cholinergic neurons, alleviating AD symptoms [94]. Memantine is a low-affinity voltage-
dependent antagonist of glutamatergic NMDA receptors. By binding to the NMDA receptor,
memantine inhibits the sustained influx of Ca2+ ions from the extracellular milieu, thereby
preventing neuronal death by excitotoxicity. Such a pathogenic mechanism can be mediated
by the Aβ oligomers that bind to NMDA receptor as agonists, favoring Ca2+ influx and neuronal
excitotoxicity [95]. Interestingly, memantine preserves physiological receptor activity, such
that released glutamate can still mediate receptor activation leading to neuronal depolarization
in postsynaptic neurons [96]. However, neither cholinesterase inhibitors nor NMDA antago‐
nists have disease-modifying effects in AD and they are generally viewed as palliative
treatments with marginal to minimal clinical efficacy, either alone or in combination. There‐
fore, only a small percentage of patients with AD respond to these treatments and these
responders normally undergo a short period of cognitive stabilization after which they again
suffer from the cognitive decline associated to largescale neuronal degeneration [97, 98]. This
scenario highlights the unmet clinical need for the treatment of AD and related conditions.
Developing disease-modifying drugs (DMDs) capable of preventing neuron degeneration and
thereby counteracting AD progression is one of the most pressing challenges of modern
pharmacology. Since the pathological process of AD begins many years before its clinical
diagnosis, the optimal time for a disease-modifying therapy may be during the prodromal
stage of AD. Therefore, clinical diagnosis of AD must be achieved when patients show no
relevant clinical signs. Indeed, the development of DMDs will require the concomitant
incorporation of reliable biomarkers to identify early stages of AD (see Section 3.3). Hitherto,
no DMDs are available for AD and although several have been tested up to phase 3, none has
yet achieved marketing approval. The recurrent failures in clinical trials raise a number of
questions about our understanding of AD pathophysiology. In this sense, the amyloid cascade
hypothesis has not only influenced the study of AD pathophysiology over the past 2 decades
but also, the choice of drug targets (see Section 2). Therefore, most clinical trials have set out
to prevent Aβ accumulation, either by inhibiting its production/aggregation or enhancing its
clearance, as well as reducing tau phosphorylation [99, 100]. However, it remains unclear if
these two hallmarks of AD are a cause or consequence of the disease. In fact, they could lie
downstream of previous molecular/cellular alterations, as a result of the disease pathology
(damage response proteins) and/or as products of an endogenous protective response to
disease-induced damage. Nonetheless, over the past 20 years the main focus of biomedical
research and the associated drug discovery programs for AD have targeted brain amyloid or
tau hyperphosphorylation, and the associated formation of neurofibrillary tangles [18].
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Mutations in the BACE-1 gene have not been related to AD but elevated levels of this enzyme
have consistently been found in both the brain and CSF of patients with AD [101–103]. Since
β-secretase activity is pathologically elevated in AD, BACE1 inhibition has been addressed as
a potential therapeutic approach to combat AD. In fact, both genetic deletion of BACE-1 and
administration of a BACE-1 inhibitor rescued cognitive deficits and lowered brain Aβ
production in AD mouse models. Interestingly, although BACE-1 has other substrates, its
inhibition was apparently free of side effects in AD mice [104, 105]. The latest generation of
small molecule BACE-1 inhibitors has achieved satisfactory brain penetration and a robust
reduction in cerebral Aβ in preclinical animal models. Furthermore, administration of most of
these inhibitors in humans also reduced Aβ and sAPPβ levels, whereas sAPPα (the α-secretase
cleavage product) was enhanced in the CSF. This observation is consistent with BACE-1
inhibition since β- and α-secretase compete for APP processing (see Figure 1). Many of these
BACE-1 inhibitors are still in phase-1 clinical trials where safety and tolerability are tested but
some of them are currently in phase 2/3, although no clinical efficacy data are as yet available
(Table 1). Interestingly, one such drug (LY2886721 from Eli Lilly Company) was discontinued
in a phase-2 trial because a number of subjects developed hepatic toxicity, although they were
not associated with the mechanism of action of BACE1 [106].
Drug  Synonyms  Company  Mechanism of
action 
Result of
study 
Clinical trial ID* Observations 
LY2886721 – Eli Lilly & Co. β-Secretase
inhibitor
Discontinued 
in phase 2
NCT01561430 Altered liver
biochemistry
AZD3293 LY3314814 Astra Zeneca/ Eli
Lilly & Co.
β-Secretase
inhibitor
Ongoing in
phase 2/3
NCT02245737 –
Verubecestat MK-8931
MK-8931-009
Merck β-Secretase
inhibitor
Ongoing in
phase 2/3
NCT01739348
NCT01953601
–
E2609 – Eisai/Biogen
Idec
β-secretase
inhibitor
Ongoing in
phase 2
NCT02322021 –
Semagacestat LY450139 Eli Lilly & Co. γ-secretase
inhibitor
Discontinued
in phase 3
NCT01035138
NCT00762411
NCT00594568
Lack of clinical
improvement
Increased risk of
skin cancer and
infections.
Avagacestat BMS-708163 Bristol-Myers
Squibb
Notch-sparing
γ-secretase
inhibitor
Discontinued
in phase 3
NCT00890890 Lack of clinical
improvement
Increased rate of
skin cancers
Begacestat GSI-953 Pfizer Notch-sparing
γ-secretase
inhibitor
Phase-1 trial
completed
NCT00547560 –
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Drug  Synonyms  Company  Mechanism of
action 
Result of
study 
Clinical trial ID* Observations 
Tarenflurbil R-flurbiprofe
MPC-7869
Myriad Genetics 
& Laboratories
γ-Secretase
modulator
Discontinued
in phase 3
NCT00105547
NCT00380276
NCT00322036
Lack of clinical
improvement
Low potency and
poor brain
penetration
Tramiprosate NC-531
Homotaurine
3APS
Neurochem, Inc Aβ aggregation
inhibitor
Discontinued
in phase 3
NCT00314912
NCT00088673
NCT00217763
Lack of clinical
improvement
Scyllo-inositol AZD-103
ELND005
Elan Corporation,
Speranza
Therapeutics,
Transition
Therapeutics, Inc.
Aβ aggregation
inhibitor
Discontinued
in phase 2
NCT00568776
NCT00934050
Lack of clinical
improvement
Rosiglitazone Avandia GlaxoSmithKline Anti-diabetic
drug 
Aβ clearance
enhancer
Discontinued
in phase 3
NCT00428090
NCT00550420
Lack of clinical
improvement
AN-1792 AIP 001 Janssen
Pfizer
Aβ-targeted
active
immunotherapy
Discontinued
in phase 2
NCT00021723 Brain inflammation
Aseptic
meningoencephalitis
Bapineuzumab AAB-001 Janssen
Pfizer
Aβ-targeted
passive
immunotherapy
Discontinued
in phase 3
NCT00676143
NCT00667810
NCT00998764
NCT00996918
Lack of clinical
improvement
Solanezumab LY2062430 Eli Lilly & Co. Aβ-targeted
passive
immunotherapy
Ongoing in
phase 3
NCT00905372
NCT00904683
NCT01127633
NCT01900665
–
Gantenerumab RO4909832
RG1450
Chugai
Pharmaceutical
Co. Ltd.
Hoffmann-La
Roche
Aβ-targeted
passive
immunotherapy
Ongoing in
phase 3
NCT01224106
NCT02051608
–
Aducanumab BIIB037 Biogen Aβ-targeted
passive
immunotherapy
Ongoing in
phase 3
NCT02477800
NCT02484547
–
Ponezumab PF-04360365 Pfizer Aβ-targeted
passive
immunotherapy
Discontinued
in phase 2
NCT00722046
NCT00945672
Lack of clinical
improvement
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Drug  Synonyms  Company  Mechanism of
action 
Result of
study 
Clinical trial ID* Observations 
Valproate Depakote,
Depakene
Abbott
Laboratories
Tau
phosphorylation 
inhibitor
Discontinued
in phase 3
NCT00071721 Lack of clinical
improvement
Brain volume loss
Lithium ** Lithium
carbonate
Public institutions Tau
phosphorylation
inhibitor
Ongoing in
phase 2
ISRCTN72046462
(see at isrctn.com)
NCT01055392
NCT02129348
NCT00088387
Discrepant results
reported
Apparently effective
in early AD
(amnestic MCI) but
not in mild-to-
moderate AD
Epothilone D BMS-241027 Bristol-Myers
Squibb
Microtubule
stabilizer
Discontinued
in phase 1
NCT01492374 No reasons reported
regarding
discontinuation in
phase 1
TPI 287 – Cortice
Biosciences 
Microtubule
stabilizer
Ongoing in
phase 1
NCT01966666
Methylthioninium 
(MT)
Methylene
Blue
Rember TM
TRx-0014
TauRx
Therapeutics Ltd
Tau aggregation
inhibitor
Discontinued
in phase 2
NCT00684944
NCT00515333
Discrepant results
reported
Blinding of phase-2
trial has been
questioned
LMT-X Methylene
Blue
TRx-0237
TauRx
Therapeutics Ltd
Tau aggregation
inhibitor
Phase 3
completed
NCT01689233
NCT01689246
NCT01626378
No results available
as yet
ACI-35 – AC Immune SA
Janssen
Tau-targeted
active
immunotherapy
Phase 1
completed
ISRCTN13033912 
(see at isrctn.com)
–
AADvac1 Axon
peptide 108
conjugated
to KLH
Axon
Neuroscience SE
Tau-targeted
active
immunotherapy
Ongoing
phase 
1
NCT02031198 –
RG7345 RO6926496 Roche Tau-targeted
passive
immunotherapy
Discontinued
in phase 1
NCT02281786 No reasons reported
regarding
discontinuation in
phase 1
Some data in this table are available at http://www.alzforum.org/therapeutics/.
*Clinical trial IDs were obtained from Clinicaltrials.gov unless specified.
**Information regarding the clinical use of lithium was obtained from [121, 122] and Clinicaltrials.gov.
Table 1. Developed disease-modifying drugs for AD treatment in clinical trials.
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Clinical mutations in PS1 are supposed to induce a loss of γ-secretase function that in turn
prevents Aβ generation and increases the Aβ 42/40 ratio (an increase in the longer vs. shorter
Aβ isoforms) [31]. Such loss of function is then translated into increased neuronal Aβ produc‐
tion, which is further potentiated with the ageing in AD mice harboring FAD mutations [23,
58]. This pathological mechanism is associated with accumulation of autophagic vesicles in
axonal dystrophies surrounding amyloid plaques, which are principally formed by long
hydrophobic isoforms of Aβ like Aβ42. Therefore, γ-secretase inhibition or modulation has
also been studied as a plausible therapeutic approach against AD, although non-specific effects
hinder the development of γ-secretase inhibitors (GSI) as DMDs given that γ-secretase also
cleaves several type-I transmembrane proteins such as the Notch receptor, N-cadherin, ErbB4,
and p75NTR (see Section 2).
Semagacestat was the first GSI to undergo clinical trials, and it reduced Aβ concentrations in
the mouse CNS and human plasma [107, 108]. Two large phase-3 trials with semagacestat were
prematurely interrupted due to serious adverse events, including hematological alterations,
and an increased risk of skin cancer and infections that were attributed to inhibition of the
Notch signaling pathway. Furthermore, a worsening of cognition was observed in AD-treated
patients [109]. Notch-sparing GSIs (second generation inhibitors) and modulators (agents that
shift γ-secretase cleavage from longer to shorter Aβ species without affecting Notch cleavage)
were then designed for clinical development. Avagacestat and begacestat were first conceived
as notch-sparing GSIs that supposedly display greater selectivity for APP than for Notch
cleavage [10], although this was recently reported not to be the case [31]. Therefore, these drugs
are also likely to fail and indeed, the poor clinical efficacy of Avagacestat was coupled to an
increased rate of skin cancers, again suggesting side effects attributable to Notch signaling
inhibition (see Table 1). Finally, some non-steroidal anti-inflammatory drugs (NSAIDs)
modulate γ-secretase (GSMs), decreasing the abundance of Aβ42 while increasing that of
Aβ38. Tarenflurbil (the R-enantiomer of flurbiprofen) was tested in a phase-3 trial but it did
not slow cognitive decline in patients, while it did increase the frequency of dizziness, anemia,
and infection. This failure of tarenflurbil was attributed to its low potency and poor brain
penetration [10, 99].
Aggregation of Aβ monomers into higher molecular weight oligomers is thought to be a key
neurotoxic event leading to neurodegeneration in the amyloid pathology [7]. For this reason,
some DMDs also target this conversion to fight AD. Tramiprosate and scyllo-inositol are two
compounds that prevent the transition from Aβ monomers to oligomers, thus favoring Aβ
clearance from the brain by insulin-degrading enzyme (IDE) and neprilysin [110]. In addition,
scyllo-inositol can also directly bind to Aβ oligomers, promoting their dissociation. Both these
drugs have been involved in phase-2 clinical trials and both reduced Aβ42 levels in the CSF
of treated patients. In a larger phase-3 study, tramiprosate failed to induce clinical improve‐
ment, and thus, further clinical evaluation is still necessary. Scyllo-inositol, also failed to
produce significant clinical improvement in a phase-2 trial. Rosiglitazone is an anti-diabetic
drug that improves spatial learning and memory abilities, and it mildly decreases Aβ42 brain
levels by activating PPARγ and upregulating IDE in AD mice [111]. This drug was involved
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in phase-2 and phase-3 clinical trials, although the inconclusive results in phase 2 were
followed by a lack of clinical efficacy in a larger phase-3 study [99, 112].
Another therapeutic approach to promote Aβ clearance was based on immunization toward
Aβ. Active immunization by vaccination stimulates the immune response to promote antibody
formation against pathogenic forms of Aβ, such as Aβ42. Active Aβ immunotherapy has been
studied since 1999 when the generation of Aβ antibodies was shown to produce clearance of
cerebral Aβ by phagocytic microglia in animal models [113]. Unfortunately, this revolutionary
approach soon suffered its first setback in a phase-2 trial to test active immunization using full
length human Aβ42 peptide, with some patients developing brain inflammation with aseptic
meningoencephalitis and provoking the termination of the clinical study [99]. Passive immu‐
notherapy is an alternative strategy and recent approaches were based on shorter Aβ immu‐
nogens, such as the humanized monoclonal antibody to Aβ1–5, bapineuzumab, which binds
to both soluble and fibrillar forms of Aβ. Despite the evidence of adverse effects in phase-1
trials, bapineuzumab advanced to phases 2 and 3 where it failed to demonstrate clinical efficacy
in patients with AD. Another antibody against Aβ is Solanezumab, a humanized monoclonal
antibody against Aβ16–24 that preferentially binds to soluble Aβ. In phase-2 trials, solanezu‐
mab was found to be safe while increasing plasma and CSF levels of Aβ40 and Aβ42, an
indication of decreased plaque load in the brain. However, solanezumab had no effect on
behavioral outcomes. Despite the lack of efficacy in phase 2, the antibody advanced to phase-3
trials in patients with mild-to-moderate AD where the primary endpoints, both cognitive and
functional, were not achieved [18]. Many other humanized antibodies have been developed,
directed at different regions of the Aβ peptide, some entering phase-3 trials (Gantenerumab
and Aducanumab) and others having been discontinued (Ponezumab; Table 1).
According to the amyloid cascade hypothesis, Aβ accumulation precedes and drives tau
hyperphosphorylation via the activation of different kinases, including cyclin dependent
kinase 5 (CDK5) and glycogen synthase kinase 3β (GSK3β) [14, 114]. Tau hyperphosphoryla‐
tion is thought to destabilizes neuronal microtubules, impairing axonal transport and leading
to neurite pathology, finally resulting in deficient synaptic function and neuronal death [115,
116] (see Section 2). In this context, DMDs were developed to inhibit tau phosphorylation, as
well as compounds that prevent tau aggregation. GSK3β is the main enzyme involved in tau
hyperphosphorylation, and lithium and valproate are both drugs that inhibit GSK3β and
reduce tau phosphorylation in animal models [117]. Unexpectedly, valproate impaired the
cognitive and functional status, and it was also associated with a reduced brain volume in
patients with AD receiving the drug in clinical trials [118]. Lithium is neuroprotective in animal
models of AD, not only via the inhibition of GSK-3β but also through the remodeling of Aβ
plaques, leading to a decrease in the number of dystrophic axons, reduced neuronal degener‐
ation and improved cognitive scores in AD mice [119, 120]. However, no conclusions have
been reached regarding the clinical efficacy of lithium for AD treatment. Some clinical trials
failed to demonstrate a protective effect of lithium on cognitive performance, although a more
recent clinical study showed that lithium reduced cognitive decline patients with early AD
(amnesic MCI) [121, 122]. Tau hyperphosphorylation compromises its ability to bind to
microtubules in AD, provoking microtubule instability. In this sense, epothilone D and TPI
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287, synthetic paclitaxel-derived microtubule-stabilizing drugs with good BBB permeability,
were assessed in phase-1 trials of safety and tolerability. Unfortunately, epothilone D was
recently discontinued (see Table 1). Tau hyperphosphorylation also provokes tau aggregation
which is also considered a key neurotoxic event in AD [123]. LMT-X is a new version of
methylene blue, a compound that was tested and discontinued in a phase-2 trial to treat AD.
LMT-X is an inhibitor of tau aggregation that specifically disrupts tau-tau interactions in the
microtubule binding region. In a phase-2 trial, this new drug slowed down the cognitive
decline in a subgroup of patients, and it is now being tested in phase-3 trials, although
information about clinical efficacy is not yet available [124, 125]. Finally, two tau-derived
peptide vaccines that stimulate active immunization entered phase I studies: AADvac1 and
ACI-35. AADvac1 is a synthetic peptide corresponding to a naturally occurring, truncated and
misfolded form of tau. ACI-35 is a liposomal vaccine containing a synthetic peptide corre‐
sponding to human protein tau sequence 393–408 (numbering according to the tau 2N4R
isoform), with phosphorylated S396 and S404 residues. Vaccination with these peptides
improves neurobehavioral deficits in AD rodents while ACI-35 is characterized by a rapid and
robust polyclonal antibody response specific to phosphorylated tau in WT and AD mice [125].
In addition, passive immunization has also been investigated using a humanized monoclonal
antibody targeting pS422 phospho-tau. In AD mice, chronic administration of this antibody
reduced hyperphosphorylated tau accumulation [126], although clinical studies with this
antibody were recently discontinued in phase 1 (see Table 1).
The aforementioned therapeutic approaches summarize the attempts to develop DMDs based
on the amyloid cascade hypothesis, principally focused on Aβ and hyperphosphorylated tau
protein. With several anti-amyloid drugs now having failed in late stage clinical trials, many
critical voices in the scientific community have questioned the validity of the amyloid
hypothesis to explain the pathophysiology of AD and as platform on which to develop DMDs
for AD therapy. Moreover, the incidence of serious side effects observed in human trials is
another drawback to the clinical development of these types of drugs, particularly when many
of these adverse effects are associated with the mechanism of action of the compounds tested.
However, the amyloid hypothesis cannot be disregarded due the lack of reliable biomarkers
to detect efficacy at early stages, and because many of the compounds in clinical trials cross
the BBB poorly or cause side effects that forced trials to be discontinued before efficacy could
be evaluated [18, 127].
5. The role of brain lipids in preventing and treating Alzheimer’s disease
5.1. Therapeutic approaches based on inhibitors of cholesterol biosynthesis
Over the last 2 decades, the relationship between cholesterol levels and the risk of developing
AD has become more evident, in turn encouraging the use of statins to treat or prevent AD
(see Section 3.1.). Statins are a group of drugs used to treat hypercholesterolemia as they inhibit
HMG-CoA reductase, the principal enzyme involved in cholesterol synthesis. In animal
models of AD, simvastatin administration to guinea pigs decreased brain and CSF Aβ levels,
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an effect that is reversed by discontinuing the treatment [128]. By contrast, simvastatin failed
to modify brain levels of Aβ in other studies but it improved the cognitive capacity of trans‐
genic AD mice [129]. Thus, it appears that simvastatin can possibly prevent cognitive decline
in AD mice without affecting amyloidogenic APP processing, in turn suggesting that the
amyloid pathology may be a consequence more than the primary causal agent of AD, possibly
due to changes in membrane lipids. In another study, lovastatin and pravastatin reduced the
amount of Aβ in the brains of AD mice, while simultaneously increasing the levels of sAPPα
[130]. Therefore, the results of preclinical research into these drugs are encouraging, although
the outcome of human studies has been inconsistent, in part due to the differences in study
design and data analysis [131].
While several observational studies in human subjects support the hypothesis that statins may
prevent AD development, other studies argue against such effects [132]. Nevertheless, some
clinical trials are investigating the use of statins in AD, such as simvastatin or atorvastatin. The
first trial to analyze the effect of simvastatin on cognitive scores and APP processing was
completed in 2003. This clinical study was performed over 12 weeks on patients with AD, and
it reported changes in APP metabolites in the CSF: sAPPα and sAPPβ levels were significantly
reduced but not those of Aβ or tau. Remarkably, a significant cognitive improvement in
response to simvastatin treatment was found in patients with AD [133]. Unexpectedly,
subsequent results based on a 12 month treatment failed to show such cognitive improvements
in the same patients, even though cholesterol metabolism was altered in the brain [134].
Unfortunately, a later larger trial performed on 406 mild-to-moderate AD patients also failed
to identify clinical benefits of simvastatin (the multicenter CLASP trial). This CLASP trial
(clinicaltrials.gov ID: #NCT00053599) evaluated the safety and efficacy of an 18 month
treatment with simvastatin to prevent AD progression. Once again, simvastatin treatment
lowered lipid levels but it did not slow the progressive AD-related decline in cognitive
performance [135]. Despite the apparent lack of clinical improvement on cognition in patients
with AD, the University of Wisconsin (Madison, USA) evaluated simvastatin in cognitively
normal people at risk of developing FAD. This study (ESPRIT study: clinicaltrials.gov ID:
#NCT00486044), compared the changes in CSF Aβ and cognitive scores following simvastatin
or placebo administration, as well as markers of cholesterol metabolism and inflammation.
Again, no specific effect of simvastatin was observed on CSF Aβ or tau levels but a improve‐
ment in terms of cognitive performance was reported [136]. As a result, a follow-up study
attempted to evaluate similar outcome measures after a longer course of simvastatin (the
SHARP study; clinicaltrials.gov ID: #NCT00939822). Additional clinical trials with a more
precise methodological design are also being developed to define the clinical efficacy of
simvastatin. For instance, the SIMaMCI study (clinicaltrials.gov ID: #NCT00842920) on 445
subjects assesses the time until participants suffer phenoconversion to dementia, with
conversion being defined as an increase in the Clinical Dementia Rating (CDR) score above
0.5. The trial also focuses on the change in cognitive scores from a healthy state to MCI and
dementia.
Other clinical studies have assessed atorvastatin, lovastatin, and pravastatin in AD. The only
clinical trial showing cognitive improvement associated with atorvastatin administration was
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a phase-2 pilot study comparing a 1-year course of atorvastatin to a placebo in patients with
mild-to-moderate-AD who were also taking a cholinesterase inhibitor and vitamin E (clini‐
caltrials.gov: #NCT00024531). This study reported trends towards benefits on cognition and
function [137, 138], leading to a larger phase-3 randomized trial involving 640 patients to
confirm the potential clinical benefits of atorvastatin in patients with mild-to-moderate AD
also treated with donepezil (the LEADe study; clinicaltrial.gov ID: #NCT00151502). Unfortu‐
nately, no clinical benefit was observed after 18 months of treatment [139, 140], and this was
considered the definitive trial on atorvastatin regarding symptomatic AD treatment. It is worth
noting that APP metabolites were not assessed in these studies and that decreased circulating
cholesterol, as well as improved neurovascular response and cerebral blood flow were found
in atorvastatin-treated patients with AD (clinicaltrials.gov: #NCT00751907) [141]. Lovastatin
has been less frequently studied in randomized AD trials, and it was shown to be efficient in
reducing serum Aβ levels in patients AD, although no cognitive evaluations were performed
(clinicaltrial.gov: #NCT00046358) [142]. In the case of pravastatin, APP processing was not
analyzed and the cognitive evaluation of treated patients revealed no significant improvement
relative to the placebo group (clinicaltrial.gov: # NCT00303277) [143].
The substantial variability in outcome from these human studies makes it difficult to ascertain
whether statins might have a beneficial role in preventing or treating AD. One possible reason
to explain such inconsistency relates to the ability of statins to cross the BBB and enter the
brain. In this respect, the chemical structure of statins can vary greatly, which justifies why
some of them cross the BBB better than others. Accordingly, simvastatin and lovastatin appear
to cross the BBB via passive diffusion, whereas pravastatin depends on an active transport
system. Although this could justify the lack of clinical effect of pravastatin in clinical trials, it
is also true that pravastatin reduced Aβ load in AD mice, suggesting that pravastatin does
reach the brain and exert its pharmacological effects [130, 144]. In this sense, clinical studies
have investigated different statins with substantial variation in BBB permeability, making it
difficult to reconcile the conflicting findings in the literature.
Another confounding factor would be the AD patient’s ApoE genotype which may affect the
effectiveness of statins in AD prevention and treatment. In fact, individuals with the ApoE4
allele may experience less benefit from statin treatment in terms of cholesterol levels than
others with the E2 or E3 alleles [145]. Therefore, although some trials in humans have taken
the ApoE genotype into account, not all do. In addition, statins have a number of pleitropic
effects on physiology and metabolism besides lowering cholesterol levels. For instance, statins
can alter the expression of genes related to cell growth, signaling, trafficking, and apoptosis,
which in turn can potentially affect the results of trials. In this sense, inhibition of HMG-CoA
reductase activity can lead to decreased isoprenylation of proteins which in turn may cause a
variety of downstream effects [146]. Thus, low isoprenoid levels may inhibit the secretory APP
pathway leading to intracellular accumulation of APP metabolites that bias their analysis in
the CSF or plasma [147].
In summary, cholesterol-lowering drugs such as statins have potential therapeutic effects for
the treatment of AD. Based on preclinical studies in animal models and clinical trials in
humans, statins represent a valuable group of compounds with promising therapeutic effects
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in AD. However, individual statins show different outcomes in terms of APP metabolism and
cognitive improvement. In part, these disparities may be explained by the variability in BBB
permeability and the different biochemical effects of these drugs observed to date.
5.2. Therapeutic approaches based on PUFAs
Neuroprotective effects of long-chain ω-3 PUFAs (see Section 3.2.) encouraged a number of
clinical trials to assess the effects of ω-3 fatty acid administration to patients with AD over a
defined time period, particularly focusing on the cognitive benefits of DHA and EPA. Inter‐
estingly, decreases in plasma DHA are associated with cognitive decline in healthy elderly
adults and DHA administration to these patients improved the physiological memory loss and
cognitive decline that frequently appears in the elderly [148] (clinicaltrials.gov ID:
#NCT0027813). However, DHA administration to patients with AD did not significantly
improve cognitive scores [80] (clinicaltrials.gov ID: #NCT00440050). Another randomized
study involving administration of a commercially available fish oil as source of DHA and EPA
only improved cognition in a small subgroup of patients with very mild cognitive dysfunction,
with no clear beneficial effects in most patients [149] (clinicaltrials.gov ID: #NCT00211159).
Finally, the most recent trial was carried out on a small group of patients with mild-to-
moderate AD who were administered fish oil containing DHA and EPA. In this pilot study,
significant recovery of cognitive capacity was evident in the patients treated with fish oil (with
or without lipoic acid supplementation) [150] (clinicaltrials.gov ID: #NCT00090402). Together,
these studies indicate that DHA supplementation may represent a plausible therapeutic
approach for the treatment of the physiological age-related cognitive decline, although it is
unclear what type of ω-3 PUFAs could be used to treat AD. Some of these discrepancies in the
different randomized studies may reflect the source of the ω-3 PUFAs administered to the
patients. As yet there is no consensus with regards the defined sources of ω-3 PUFAs or a
standard ratio or dose of DHA and EPA: Quinn et al. [80] evaluated 2 g/day DHA, Freund-
Levi et al. [149] evaluated the effect of fish oil administration with a DHA and EPA content of
1.7 and 0.6 g/day, respectively (EPAX 1500 TG; Pronova Biocare, Norway), and Shinto et al.
[150] evaluated a fish oil daily dose containing 675 mg DHA and 975 mg EPA, the latter trial
being the only efficacious treatment against AD in humans and having a different DHA:EPA
ratio with respect to the former.
It is likely that differences in the source of ω-3 PUFAs together with variable DHA:EPA ratios
might explain the variation in the results observed when treating AD patients with long-chain
ω-3 PUFAs. Moreover, the presence of mercury in some fish oil supplements may provoke
some neurological problems that could counteract the beneficial effects of DHA and related
compounds. In this context, ω-3 PUFAs also exert their physiological function through the
production of hydroxylated bioactive derivatives, such as NPD1 (see Section 3.2.). In fact, it
has been demonstrated that NPD1 levels are dramatically reduced in the AD brain, even more
so than DHA [68]. These data suggest that abnormally low levels of DHA in AD would be
accompanied by impaired conversion of this fatty acid into NPD1 and other RVs. In fact,
reduced levels of 15-LOX, the key enzyme involved in the generation of the D-series RVs and
protectins, were observed in the brain of patients with AD, in turn demonstrating that lipid
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second messenger generation from DHA is impaired in AD [68]. Assuming that the conversion
of DHA into hydroxylated derivatives is needed to mediate DHA-related physiological
activity, such 15-LOX modifications could at least partially explain why DHA administration
did not improve cognition in patients with AD. In this context, it is noteworthy that some
cognitive improvement was observed when fish oil alone was used as the source of ω-3 PUFAs,
suggesting that these oils might contain other PUFAs that impart neuroprotection independ‐
ently of DHA and EPA (hydroxylated PUFAs such as RVs or other PUFA derivatives) [81].
This hypothesis is supported by the high efficacy of HDHA(see below DHALifort) on cognitive
score and by the aforementioned epidemiological meta-analysis showing an inverse correla‐
tion between AD incidence and fish oil intake but not with DHA/EPA (ω-3 PUFA) intake (see
Section 3.2) [78].
DHA-derived NPD1 produces many beneficial effects in animal and cell models of AD [75].
On the one hand, NPD1 suppresses Aβ42 peptide shedding by downregulating BACE-1
activity while enhancing α-secretase activity, thereby upregulating sAPPα levels and shifting
the cleavage of APP from the amyloidogenic to the non-amyloidogenic pathway. Thus, NPD1
stimulated secretion of sAPPα strengthens neurotrophic signaling and prevents Aβ oligomer
neurotoxicity, which may in turn be accompanied by a number of beneficial effects, such as
the prevention of neuronal and axonal injury, improved neuronal plasticity, and enhanced
learning memory [151–153]. In addition, like other RVs, NPD1 also displays anti-inflammatory
properties. Indeed, NPD1 administration decreases Aβ42-triggered expression of the pro-
inflammatory COX-2 and of B-94 (a TNF-α-inducible pro-inflammatory factor), and it prevents
apoptosis in cultured cells by upregulating the expression of anti-apoptotic members of the
Bcl-2 protein family.
The neuroprotective properties of NPD1 have encouraged the development of new pharma‐
cological approaches based on hydroxylated derivatives of ω-3 PUFAs to treat AD. Regardless
of the use of natural RVs and protectins to treat inflammatory and neurodegenerative diseases
[154], synthetic ω-3-PUFA bioactive hydroxyl derivatives have also been used to treat such
disorders. This kind of therapeutic approach, aimed at modulating brain lipids to treat
neurological diseases, is framed within so-called membrane lipid therapy (MLT) [155–157]. In
this context, a novel hydroxylated derivative named HDHA (2-hydroxy-docosahexanoic acid)
has been proposed as a promising therapeutic approach to treat AD. HDHA (DHALifort;
PharmaConcept, Hungary) administration influences the brain lipid composition, increasing
the PE species carrying long-chain PUFAs, which are significantly reduced in patients with
AD (see Section 3.3.). Upon normalization of the membrane lipid composition by HDHA
treatment, the membrane structure recovers the presence of liquid-disordered prone mem‐
brane structures [158] (Figure 4). These lipid changes are paralleled with a reduction in Aβ
accumulation and tau hyperphosphorylation, and recovery of cognitive scores in a transgenic
mouse model of AD (5xFAD mice) [159, 160] (see Figure 4).
HDHA also enhances the survival of neuron-like cells exposed to different insults, such as
oligomeric Aβ and NMDA-mediated neurotoxicity (in vitro), and it promotes hippocampal
neuronal cell proliferation in 5XFAD mice in vivo [159, 160], suggesting that HDHA induced
neuroregeneration both in vivo and in vitro, which in part may explain its efficacy against
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neurodegeneration and memory loss. As part of its mechanism of action, HDHA dampens the
binding affinity of oligomeric and fibrillar Aβ to lipid-raft membrane domains. Moreover, it
enhances the unfolded protein response (UPR) and autophagy in neuron-like cells, which in
turn may promote neuronal survival [160, 161]. In this sense, although the molecular role of
autophagy in AD is complex and still largely unknown, it is thought that activation of salvage
autophagy would avoid the intracellular accumulation of Aβ and its precursors by reducing
the neuritic pathology (see Figure 2) [162, 163]. Therefore, the pleitropic effects of HDHA have
proven beneficial to treat AD, suggesting that its molecular target is an upstream entity such
as the membrane lipid bilayer. Thus, the normalization of the PE, DHA, cholesterol, and SM
content mediated by HDHA would restore membrane lipid structure, which in turn would
regulate amyloidogenic secretase activity tau phosphorylation and neuronal degeneration.
Figure 4. Proof of concept for the use of HDHA in AD mice and the proposed molecular mechanism of action. (A)
Diagrams showing representative outlines of control and AD mice (5xFAD mice) that received HDHA or the vehicle
alone, in the Radial Arm Maze test (RAM). A black point at the end of one arm represents where the mice find a food
pellet. (B) Quantitative analysis of test performance is addressed by quantifying working (reentry of an arm already
visited) and reference (entry into an unbaited arm) memory errors. Both parameters increased significantly in AD mice
while HDHA treatment prevented such behavioral impairment until cognitive scores were almost totally reverted to
those of the controls. Bars represent the mean ± SEM. One-way ANOVA followed by Bonferroni’s post hoc test: *p <
0.05, difference relative to healthy controls; #: p < 0.05 difference relative to the untreated AD group. C) Postulated
mechanism of action for HDHA. HDHA enriches brain membranes in PE carrying DHA and other long PUFAs. These
lipid changes may influence the structure of the cell membrane by promoting the appearance of liquid-disordered
prone structures and potentially preventing AD-related cell signaling by: (i) downregulating APP amyloidogenic proc‐
essing and Aβ-induced tau protein hyperphosphorylation; and (ii) decreasing neuron vulnerability to extracellular tox‐
ic agents such as oligomeric Aβ. Together, this evidence supports a neuroprotective role of HDHA that may be
associated with the improved cognitive capabilities observed in AD mice. Adapted from [159, 160].
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Interestingly, the cellular heat shock response (HSP) depends on the plasma membrane
composition, such that increased membrane fluidity is related to enhanced expression of heat-
shock proteins (HSP) [164]. In this context, these proteins (particularly Hsp70, Hsp60, and
Hsp27) are involved in the mechanism of action of lithium in compacting Aβ plaques, lowering
the density of dystrophic neurites and preventing neuronal degeneration in a mouse model of
AD [119]. Therefore, lipid derivatives like HDHA that enhance membrane fluidity might also
reduce the neurite pathology and prevent neuronal loss in AD via a mechanism involving Hsp
expression. Regardless of amyloid production and the neuritic pathology, inflammation is also
a key player in AD. In this sense, another synthetic hydroxyl derivative of ARA, 2-HARA (2-
hydroxy-arachidonic acid) is a COX-1 and COX-2 inhibitor [165]. The inhibitory effect over
COX-1 has been related to alternative microglia activation, as well as reduced Aβ production
and tau hyperphosphorylation in a transgenic model of AD [166]. Thus, 2-HARA may be a
promising therapeutic approach to mitigate the inflammatory component of AD, driving
microglia activation towards an alternative neuroprotective phenotype, and reducing AD-
related amyloid and tau pathologies. To summarize, MLT is a therapeutic concept targeting
membrane lipids that could be used to treat neurological disorders such as AD. In this context,
recent findings about ω-3 PUFA RV-like mediators, such as HDHA and 2-HARA, offer a wide
range of possibilities to design new bioactive compounds to treat neurodegenerative diseases.
6. Concluding remarks
After adipose tissue, the human brain is the organ with the largest amount of lipids in the
body. There is compelling evidence that lipid homeostasis is altered in AD, suggesting that
the plasma membrane lipid composition and structure plays a critical role in the pathophysi‐
ology of AD and hence in its therapy. Therefore, lipid alterations might be responsible for other
downstream neuropathological hallmarks of AD, including amyloid and neurite pathologies,
as well as inflammation and neuron loss, which eventually causes the cognitive deterioration
evident in patients with AD. Accordingly, a number of clinical trials have been set up to
investigate how the regulation of cholesterol and PUFA hydroxyl derivatives such as HDHA
may constitute promising therapeutic approaches to treat this devastating condition.
7. Review criteria
The PubMed database (NCBI, National Library of Medicine, USA) was searched for relevant,
both original and review, articles using the keywords mentioned at the beginning of the
present chapter either by separate or with multiple combinations. The papers were selected
accordingly to their adhesion to the main subject of the present review and the expert authors’
knowledge of the field. In addition, interesting and useful information has been achieved from
http://www.alzforum.org/ and http://clinicaltrials.gov/, as well as from books at the Library
of the University of the Balearic Islands (Palma de Mallorca, Spain).
Brain Lipids in the Pathophysiology and Treatment of Alzheimer’s Disease
http://dx.doi.org/10.5772/64757
153
Acknowledgements
Springer is the original publisher of images shown in Figure 2. These pictures were reproduced
with permission from Springer and were adapted from [12] (please see full credits in the
reference list). The authors wish to thank the original publisher as well as the original authors
(Dr. Isidre Ferrer and co-workers) for allowing reproduction of these images in the present
work. Information concerning clinical trials of several drugs has been obtained from the
website http://www.alzforum.org/therapeutics. This work was supported in part by grants
from the Spanish Ministerio de Economía y Competitividad (BIO2010-21132,
IPT-010000-2010-16, BIO2013-49006-C2-1-R, RTC-2015-3542, RTC-2015-4094 to PVE and XB),
with co-financing from EU FEDER funds, by grants to Research Groups of Excellence from the
Govern de les Illes Balears, Spain (PVE), and by the Marathon Foundation (Spain). MT was a
recipient of a Torres-Quevedo contract from the Spanish Ministerio de Economía y Competi‐
tividad.
Conflict of interest
MT was supported by a Torres-Quevedo Research Contract granted to Lipopharma Thera‐
peutics, S.L., from the Ministerio de Economía y Competitividad (Spanish Government).
Lipopharma Therapeutics, S.L., is a spin-off company from the University of the Balearic
Islands.
Author details
Manuel Torres1,2*, Xavier Busquets1 and Pablo V. Escribá1*
*Address all correspondence to: manuel.torres.phd@gmail.com and Pablo.escriba@uib.es
1 Laboratory of Molecular Cell Biomedicine, University of the Balearic Islands, Palma de
Mallorca, Spain
2 Lipopharma Therapeutics S.L., Palma de Mallorca, Spain
References
[1] Castellani RJ, Rolston RK, Smith MA. Alzheimer disease. Dis Mon. 2010;56(9):484–546.
[2] Annaert W, Cupers P, Saftig P, De Strooper B. Presenilin function in APP processing.
Ann N Y Acad Sci. 2000;920:158–64.
[3] Price DL, Sisodia SS. Mutant genes in familial Alzheimer’s disease and transgenic
models. Annu Rev Neurosci. 1998;21:479–505.
Update on Dementia154
[4] Harman D. Alzheimer’s disease pathogenesis: role of aging. Ann N Y Acad Sci.
2006;1067:454–60.
[5] De Strooper B. Proteases and proteolysis in Alzheimer disease: a multifactorial view
on the disease process. Physiol Rev. 2010;90(2):465–94.
[6] Xiang Y, Lam SM, Shui G. What can lipidomics tell us about the pathogenesis of
Alzheimer disease? Biol Chem. 2015;396(12):1281–91.
[7] Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the
Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8(2):101–12.
[8] Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science.
1992;256(5054):184–5.
[9] Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and
problems on the road to therapeutics. Science. 2002;297(5580):353–6.
[10] De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential
in Alzheimer disease. Nat Rev Neurol. 2010;6(2):99–107.
[11] Duyckaerts C, Delatour B, Potier M-C. Classification and basic pathology of Alzheimer
disease. Acta Neuropathol. 2009;118(1):5–36.
[12] Pérez-Gracia E, Torrejón-Escribano B, Ferrer I. Dystrophic neurites of senile plaques in
Alzheimer’s disease are deficient in cytochrome c oxidase. Acta Neuropathol.
2008;116(3):261–8.
[13] Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. Soluble amyloid beta-
protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphory‐
lation and neuritic degeneration. Proc Natl Acad Sci U S A. 2011;108(14):5819–24.
[14] Spires-Jones TL, Stoothoff WH, de Calignon A, Jones PB, Hyman BT. Tau pathophysi‐
ology in neurodegeneration: a tangled issue. Trends Neurosci. 2009;32(3):150–9.
[15] Heneka MT, O’Banion MK. Inflammatory processes in Alzheimer’s disease. J Neuro‐
immunol. 2007;184(1–2):69–91.
[16] Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci. 2007;120(Pt
23):4081–91.
[17] Krstic D, Knuesel I. The airbag problem-a potential culprit for bench-to-bedside
translational efforts: relevance for Alzheimer’s disease. Acta Neuropathol Commun.
2013;1:62.
[18] Mullane K, Williams M. Alzheimer’s therapeutics: continued clinical failures question
the validity of the amyloid hypothesis-but what lies beyond? Biochem Pharmacol.
2013;85(3):289–305.
[19] Wong PC, Cai H, Borchelt DR, Price DL. Genetically engineered mouse models of
neurodegenerative diseases. Nat Neurosci. 2002;5(7):633–9.
Brain Lipids in the Pathophysiology and Treatment of Alzheimer’s Disease
http://dx.doi.org/10.5772/64757
155
[20] Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee J-H, et al. Macroau‐
tophagy – a novel Beta-amyloid peptide-generating pathway activated in Alzheimer’s
disease. J Cell Biol. 2005;171(1):87–98.
[21] Zhang X-M, Cai Y, Xiong K, Cai H, Luo X-G, Feng J-C, et al. Beta-secretase-1 elevation
in transgenic mouse models of Alzheimer’s disease is associated with synaptic/axonal
pathology and amyloidogenesis: implications for neuritic plaque development. Eur J
Neurosci. 2009;30(12):2271–83.
[22] Doehner J, Genoud C, Imhof C, Krstic D, Knuesel I. Extrusion of misfolded and
aggregated proteins--a protective strategy of aging neurons? Eur J Neurosci.
2012;35(12):1938–50.
[23] Sanchez-Varo R, Trujillo-Estrada L, Sanchez-Mejias E, Torres M, Baglietto-Vargas D,
Moreno-Gonzalez I, et al. Abnormal accumulation of autophagic vesicles correlates
with axonal and synaptic pathology in young Alzheimer’s mice hippocampus. Acta
Neuropathol. 2012;123(1):53–70.
[24] Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nat Rev Neurosci.
2006;7(4):278–94.
[25] Krstic D, Knuesel I. Deciphering the mechanism underlying late-onset Alzheimer
disease. Nat Rev Neurol. 2013;9(1):25–34.
[26] Knowles JK, Rajadas J, Nguyen T-VV, Yang T, LeMieux MC, Vander Griend L, et al.
The p75 neurotrophin receptor promotes amyloid-beta(1–42)-induced neuritic dystro‐
phy in vitro and in vivo. J Neurosci. 2009;29(34):10627–37.
[27] Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al.
Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14(4):388–405.
[28] Jimenez S, Baglietto-Vargas D, Caballero C, Moreno-Gonzalez I, Torres M, Sanchez-
Varo R, et al. Inflammatory response in the hippocampus of PS1M146L/APP751SL
mouse model of Alzheimer’s disease: age-dependent switch in the microglial pheno‐
type from alternative to classic. J Neurosci. 2008;28(45):11650–61.
[29] Wakabayashi T, De Strooper B. Presenilins: members of the gamma-secretase quartets,
but part-time soloists too. Physiology (Bethesda). 2008;23:194–204.
[30] De Strooper B, Annaert W. Novel research horizons for presenilins and γ-secretases in
cell biology and disease. Annu Rev Cell Dev Biol. 2010;26:235–60.
[31] Chávez-Gutiérrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M,
et al. The mechanism of γ-Secretase dysfunction in familial Alzheimer disease. EMBO
J. 2012;31(10):2261–74.
[32] Bentahir M, Nyabi O, Verhamme J, Tolia A, Horré K, Wiltfang J, et al. Presenilin clinical
mutations can affect gamma-secretase activity by different mechanisms. J Neurochem.
2006;96(3):732–42.
Update on Dementia156
[33] Thimiri Govinda Raj DB, Ghesquière B, Tharkeshwar AK, Coen K, Derua R, Vander‐
schaeghe D, et al. A novel strategy for the comprehensive analysis of the biomolecular
composition of isolated plasma membranes. Mol Syst Biol. 2011;7:541.
[34] Tamboli IY, Prager K, Thal DR, Thelen KM, Dewachter I, Pietrzik CU, et al. Loss of
gamma-secretase function impairs endocytosis of lipoprotein particles and membrane
cholesterol homeostasis. J Neurosci. 2008;28(46):12097–106.
[35] Martins IJ, Hone E, Foster JK, Sünram-Lea SI, Gnjec A, Fuller SJ, et al. Apolipoprotein
E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer’s
disease and cardiovascular disease. Mol Psychiatry. 2006;11(8):721–36.
[36] Bu G. Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogen‐
esis and therapy. Nat Rev Neurosci. 2009;10(5):333–44.
[37] Martins IJ, Berger T, Sharman MJ, Verdile G, Fuller SJ, Martins RN. Cholesterol
metabolism and transport in the pathogenesis of Alzheimer’s disease. J Neurochem.
2009;111(6):1275–308.
[38] Poirier J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer’s
disease. Neurobiol Aging. 2005;26(3):355–61.
[39] Rapp A, Gmeiner B, Hüttinger M. Implication of apoE isoforms in cholesterol metab‐
olism by primary rat hippocampal neurons and astrocytes. Biochimie. 2006;88(5):473–
83.
[40] Launer LJ, White LR, Petrovitch H, Ross GW, Curb JD. Cholesterol and neuropatho‐
logic markers of AD: a population-based autopsy study. Neurology. 2001;57(8):1447–
52.
[41] Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M, Manjon M, et
al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer
amyloid pathology. Neurology. 2003;61(2):199–205.
[42] Puglielli L, Tanzi RE, Kovacs DM. Alzheimer’s disease: the cholesterol connection. Nat
Neurosci. 2003;6(4):345–51.
[43] Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors
and risk of dementia in late life. Neurology. 2005;64(2):277–81.
[44] Vetrivel KS, Thinakaran G. Membrane rafts in Alzheimer’s disease beta-amyloid
production. Biochim Biophys Acta. 2010;1801(8):860–7.
[45] Ledesma MD, Dotti CG. Amyloid excess in Alzheimer’s disease: what is cholesterol to
be blamed for? FEBS Lett. 2006;580(23):5525–32.
[46] Bandaru VVR, Troncoso J, Wheeler D, Pletnikova O, Wang J, Conant K, et al. ApoE4
disrupts sterol and sphingolipid metabolism in Alzheimer’s but not normal brain.
Neurobiol Aging. 2009;30(4):591–9.
Brain Lipids in the Pathophysiology and Treatment of Alzheimer’s Disease
http://dx.doi.org/10.5772/64757
157
[47] Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA, et al. Comparative
lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem.
2012;287(4):2678–88.
[48] Cutler  RG,  Kelly  J,  Storie  K,  Pedersen WA, Tammara A,  Hatanpaa K,  et  al.
Involvement  of  oxidative stress-induced abnormalities  in  ceramide and cholester‐
ol  metabolism in  brain  aging and Alzheimer’s  disease.  Proc  Natl  Acad Sci  U S
A.  2004;101(7):2070–5.
[49] Ledesma MD, Abad-Rodriguez J, Galvan C, Biondi E, Navarro P, Delacourte A, et al.
Raft disorganization leads to reduced plasmin activity in Alzheimer’s disease brains.
EMBO Rep. 2003;4(12):1190–6.
[50] Lai AY, McLaurin J. Mechanisms of amyloid-Beta peptide uptake by neurons: the role
of lipid rafts and lipid raft-associated proteins. Int J Alzheimers Dis. 2010;2011:548380.
[51] Kalvodova L, Kahya N, Schwille P, Ehehalt R, Verkade P, Drechsel D, et al. Lipids as
modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingo‐
lipids, and anionic phospholipids in vitro. J Biol Chem. 2005;280(44):36815–23.
[52] Holmes O, Paturi S, Ye W, Wolfe MS, Selkoe DJ. Effects of membrane lipids on the
activity and processivity of purified γ-secretase. Biochemistry. 2012;51(17):3565–75.
[53] Askarova S, Yang X, Lee JCM. Impacts of membrane biophysics in Alzheimer’s disease:
from amyloid precursor protein processing to Aβ peptide-induced membrane changes.
Int J Alzheimer’s Dis. 2011;2011:134971.
[54] Runz H, Rietdorf J, Tomic I, de Bernard M, Beyreuther K, Pepperkok R, et al. Inhibition
of intracellular cholesterol transport alters presenilin localization and amyloid precur‐
sor protein processing in neuronal cells. J Neurosci. 2002;22(5):1679–89.
[55] Tamboli IY, Hampel H, Tien NT, Tolksdorf K, Breiden B, Mathews PM, et al. Sphin‐
golipid storage affects autophagic metabolism of the amyloid precursor protein and
promotes Abeta generation. J Neurosci. 2011;31(5):1837–49.
[56] Lazarov O, Morfini GA, Pigino G, Gadadhar A, Chen X, Robinson J, et al. Impairments
in fast axonal transport and motor neuron deficits in transgenic mice expressing familial
Alzheimer’s disease-linked mutant presenilin 1. J Neurosci. 2007;27(26):7011–20.
[57] Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, et al. Autophagy induction and
autophagosome clearance in neurons: relationship to autophagic pathology in Alz‐
heimer’s disease. J Neurosci. 2008;28(27):6926–37.
[58] Torres  M,  Jiménez S,  Sánchez-Varo R,  Navarro  V,  Trujillo-Estrada L,  Sánchez-
Mejias  E,  et  al.  Defective  lysosomal  proteolysis  and axonal  transport  are  early
pathogenic  events  that  worsen with  age  leading to  increased APP metabolism
and synaptic  Abeta  in  transgenic  APP/PS1 hippocampus.  Mol  Neurodegener.
2012;7:59.  Epub 2012/11/24.
Update on Dementia158
[59] Bhat NR, Thirumangalakudi L. Increased tau phosphorylation and impaired brain
insulin/IGF signaling in mice fed a high fat/high cholesterol diet. J Alzheimers Dis.
2013;36(4):781–9.
[60] Rushworth JV, Griffiths HH, Watt NT, Hooper NM. Prion protein-mediated toxicity of
amyloid-β oligomers requires lipid rafts and the transmembrane LRP1. J Biol Chem.
2013;288(13):8935–51.
[61] Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, et al.
Neurotoxicity of Alzheimer’s disease Aβ peptides is induced by small changes in the
Aβ42 to Aβ40 ratio. EMBO J. 2010;29(19):3408–20.
[62] Martins IC, Kuperstein I, Wilkinson H, Maes E, Vanbrabant M, Jonckheere W, et al.
Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning
in mice. EMBO J. 2008;27(1):224–33.
[63] Ibarguren M, López DJ, Escribá PV. The effect of natural and synthetic fatty acids on
membrane structure, microdomain organization, cellular functions and human health.
Biochim Biophys Acta. 2014;1838(6):1518–28.
[64] Plourde M, Fortier M, Vandal M, Tremblay-Mercier J, Freemantle E, Bégin M, et al.
Unresolved issues in the link between docosahexaenoic acid and Alzheimer’s disease.
Prostaglandins Leukot Essent Fatty Acids. 2007;77(5–6):301–8.
[65] Söderberg M, Edlund C, Kristensson K, Dallner G. Fatty acid composition of brain
phospholipids in aging and in Alzheimer’s disease. Lipids. 1991;26(6):421–5.
[66] Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR. Regional membrane
phospholipid alterations in Alzheimer’s disease. Neurochem Res. 1998;23(1):81–8.
[67] Han X, Holtzman DM, McKeel DW. Plasmalogen deficiency in early Alzheimer’s
disease subjects and in animal models: molecular characterization using electrospray
ionization mass spectrometry. J Neurochem. 2001;77(4):1168–80.
[68] Lukiw WJ, Cui J-G, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, et al. A role for
docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer
disease. J Clin Invest. 2005;115(10):2774–83.
[69] Astarita G, Jung K-M, Berchtold NC, Nguyen VQ, Gillen DL, Head E, et al. Deficient
liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in
Alzheimer’s disease. PLoS One. 2010;5(9):e12538.
[70] Belkouch M, Hachem M, Elgot A, Van AL, Picq M, Guichardant M, et al. The pleiotropic
effects of omega-3 docosahexaenoic acid on the hallmarks of Alzheimer’s disease. J
Nutr Biochem. 2016;38:1–11.
[71] Su H-M. Mechanisms of n-3 fatty acid-mediated development and maintenance of
learning memory performance. J Nutr Biochem. 2010;21(5):364–73.
Brain Lipids in the Pathophysiology and Treatment of Alzheimer’s Disease
http://dx.doi.org/10.5772/64757
[72] Martín V, Fabelo N, Santpere G, Puig B, Marín R, Ferrer I, et al. Lipid alterations in lipid
rafts from Alzheimer’s disease human brain cortex. J Alzheimers Dis. 2010;19(2):489–
502.
[73] Shaikh SR. Biophysical and biochemical mechanisms by which dietary N-3 polyunsa‐
turated fatty acids from fish oil disrupt membrane lipid rafts. J Nutr Biochem.
2012;23(2):101–5.
[74] Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature.
2014;510(7503):92–101.
[75] Stark DT, Bazan NG. Neuroprotectin D1 induces neuronal survival and downregula‐
tion of amyloidogenic processing in Alzheimer’s disease cellular models. Mol Neuro‐
biol. 2011;43(2):131–8.
[76] Zhao Y, Calon F, Julien C, Winkler JW, Petasis NA, Lukiw WJ, et al. Docosahexaenoic
acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARγ-
mediated mechanisms in Alzheimer’s disease models. PLoS One. 2011;6(1):e15816.
[77] Simopoulos AP. Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic
variation: nutritional implications for chronic diseases. Biomed Pharmacother.
2006;60(9):502–7.
[78] Wu S, Ding Y, Wu F, Li R, Hou J, Mao P. Omega-3 fatty acids intake and risks of
dementia and Alzheimer’s disease: a meta-analysis. Neurosci Biobehav Rev. 2015;48:1–
9.
[79] Barberger-Gateau P, Raffaitin C, Letenneur L, Berr C, Tzourio C, Dartigues JF, et al.
Dietary patterns and risk of dementia: the Three-City cohort study. Neurology.
2007;69(20):1921–30.
[80] Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, et al.
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a
randomized trial. JAMA. 2010;304(17):1903–11.
[81] Hong S, Tjonahen E, Morgan EL, Lu Y, Serhan CN, Rowley AF. Rainbow trout
(Oncorhynchus mykiss) brain cells biosynthesize novel docosahexaenoic acid-derived
resolvins and protectins—mediator lipidomic analysis. Prostaglandins Other Lipid
Mediat. 2005;78(1–4):107–16.
[82] Afshordel S, Hagl S, Werner D, Röhner N, Kögel D, Bazan NG, et al. Omega-3 poly‐
unsaturated fatty acids improve mitochondrial dysfunction in brain aging—impact of
Bcl-2 and NPD-1 like metabolites. Prostaglandins Leukot Essent Fatty Acids.
2015;92:23–31.
[83] Gómez-Isla T, Price JL, McKeel DW, Morris JC, Growdon JH, Hyman BT. Profound loss
of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease. J
Neurosci. 1996;16(14):4491–500.
Update on Dementia160
[84] Ritter A, Cummings J. Fluid biomarkers in clinical trials of Alzheimer’s disease
therapeutics. Front Neurol. 2015;6:186.
[85] Khan TK, Alkon DL. Peripheral biomarkers of Alzheimer’s disease. J Alzheimers Dis.
2015;44(3):729–44.
[86] Orešič M, Hyötyläinen T, Herukka S-K, Sysi-Aho M, Mattila I, Seppänan-Laakso T, et
al. Metabolome in progression to Alzheimer’s disease. Transl Psychiatry. 2011;1:e57.
[87] Proitsi P, Kim M, Whiley L, Pritchard M, Leung R, Soininen H, et al. Plasma lipidomics
analysis finds long chain cholesteryl esters to be associated with Alzheimer’s disease.
Transl Psychiatry. 2015;5:e494.
[88] Walter A, Korth U, Hilgert M, Hartmann J, Weichel O, Hilgert M, et al. Glycerophos‐
phocholine is elevated in cerebrospinal fluid of Alzheimer patients. Neurobiol Aging.
2004;25(10):1299–303.
[89] Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, et al.
Plasma phospholipids identify antecedent memory impairment in older adults. Nat
Med. 2014;20(4):415–8.
[90] Olazarán J, Gil-de-Gómez L, Rodríguez-Martín A, Valentí-Soler M, Frades-Payo B,
Marín-Muñoz J, et al. A blood-based, 7-metabolite signature for the early diagnosis of
Alzheimer’s disease. J Alzheimers Dis. 2015;45(4):1157–73.
[91] Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR, et al. Metabolomics in early
Alzheimer’s disease: identification of altered plasma sphingolipidome using shotgun
lipidomics. PLoS One. 2011;6(7):e21643.
[92] Mielke MM, Bandaru VVR, Haughey NJ, Rabins PV, Lyketsos CG, Carlson MC. Serum
sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol
Aging. 2010;31(1):17–24.
[93] Zambón D, Quintana M, Mata P, Alonso R, Benavent J, Cruz-Sánchez F, et al. Higher
incidence of mild cognitive impairment in familial hypercholesterolemia. Am J Med.
2010;123(3):267–74.
[94] Kása P, Rakonczay Z, Gulya K. The cholinergic system in Alzheimer’s disease. Prog
Neurobiol. 1997;52(6):511–35.
[95] Texidó L, Martín-Satué M, Alberdi E, Solsona C, Matute C. Amyloid β peptide
oligomers directly activate NMDA receptors. Cell Calcium. 2011;49(3):184–90.
[96] Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine
in the treatment of Alzheimer’s disease. CNS Drug Rev. 2003;9(3):275–308.
[97] Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness
of cholinesterase inhibitors and memantine for treating dementia: evidence review for
a clinical practice guideline. Ann Intern Med. 2008;148(5):379–97.
Brain Lipids in the Pathophysiology and Treatment of Alzheimer’s Disease
http://dx.doi.org/10.5772/64757
161
[98] Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt H-P, van den Bussche H. Choli‐
nesterase inhibitors for patients with Alzheimer’s disease: systematic review of
randomised clinical trials. BMJ. 2005;331(7512):321–7.
[99] Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F. New pharmacological strategies
for treatment of Alzheimer’s disease: focus on disease modifying drugs. Br J Clin
Pharmacol. 2012;73(4):504–17.
[100] Caraci F, Bosco P, Leggio GM, Malaguarnera M, Drago F, Bucolo C, et al. Clinical
pharmacology of novel anti-Alzheimer disease modifying medications. Curr Top Med
Chem. 2013;13(15):1853–63.
[101] Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME,
et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch
Neurol. 2008;65(8):1102–7.
[102] Hébert SS, Horré K, Nicolaï L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN,
et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates
with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A.
2008;105(17):6415–20.
[103] O’Connor T, Sadleir KR, Maus E, Velliquette RA, Zhao J, Cole SL, et al. Phosphorylation
of the translation initiation factor eIF2alpha increases BACE1 levels and promotes
amyloidogenesis. Neuron. 2008;60(6):988–1009.
[104] Chang W-P, Huang X, Downs D, Cirrito JR, Koelsch G, Holtzman DM, et al. Beta-
secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic
mice. FASEB J. 2011;25(2):775–84.
[105] Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, et al. BACE1
deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of
Alzheimer’s disease. Neuron. 2004;41(1):27–33.
[106] Vassar R. BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease. Alzheimers
Res Ther. 2014;6(9):89.
[107] Henley DB, May PC, Dean RA, Siemers ER. Development of semagacestat (LY450139),
a functional gamma-secretase inhibitor, for the treatment of Alzheimer’s disease.
Expert Opin Pharmacother. 2009;10(10):1657–64.
[108] Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, et
al. A gamma-secretase inhibitor decreases amyloid-beta production in the central
nervous system. Ann Neurol. 2009;66(1):48–54.
[109] Doody RS,  Raman R,  Farlow M,  Iwatsubo T,  Vellas  B,  Joffe  S,  et  al.  A phase  3
trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med. 2013;369(4):
341–50.
Update on Dementia162
[110] Numata K, Kaplan DL. Mechanisms of enzymatic degradation of amyloid Beta
microfibrils generating nanofilaments and nanospheres related to cytotoxicity.
Biochemistry. 2010;49(15):3254–60.
[111] Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR. Rosiglita‐
zone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol.
2006;199(2):265–73.
[112] Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, et al.
Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a
randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn
Disord. 2010;30(2):131–46.
[113] Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization
with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.
Nature. 1999;400(6740):173–7.
[114] Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge
for neurodegenerative disease. Trends Mol Med. 2009;15(3):112–9.
[115] Kanaan NM, Pigino GF, Brady ST, Lazarov O, Binder LI, Morfini GA. Axonal degen‐
eration in Alzheimer’s disease: when signaling abnormalities meet the axonal transport
system. Exp Neurol. 2013;246:44–53.
[116] Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, et al. Extensive
involvement of autophagy in Alzheimer disease: an immuno-electron microscopy
study. J Neuropathol Exp Neurol. 2005;64(2):113–22.
[117] Tariot PN, Aisen PS. Can lithium or valproate untie tangles in Alzheimer’s disease? J
Clin Psychiatry. 2009;70(6):919–21.
[118] Fleisher AS, Truran D, Mai JT, Langbaum JBS, Aisen PS, Cummings JL, et al. Chronic
divalproex sodium use and brain atrophy in Alzheimer disease. Neurology.
2011;77(13):1263–71.
[119] Trujillo-Estrada L, Jimenez S, De Castro V, Torres M, Baglietto-Vargas D, Moreno-
Gonzalez I, et al. In vivo modification of Abeta plaque toxicity as a novel neuroprotective
lithium-mediated therapy for Alzheimer’s disease pathology. Acta Neuropathol
Commun. 2013;1(1):73.
[120] Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, Squire A, et al. GSK-3beta
inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila.
Mol Psychiatry. 2004;9(5):522–30.
[121] Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-
modifying properties of long-term lithium treatment for amnestic mild cognitive
impairment: randomised controlled trial. Br J Psychiatry. 2011;198(5):351–6.
Brain Lipids in the Pathophysiology and Treatment of Alzheimer’s Disease
http://dx.doi.org/10.5772/64757
163
[122] Hampel H, Ewers M, Bürger K, Annas P, Mörtberg A, Bogstedt A, et al. Lithium trial
in Alzheimer’s disease: a randomized, single-blind, placebo-controlled, multicenter 10-
week study. J Clin Psychiatry. 2009;70(6):922–31.
[123] Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J,
Jackson GR, et al. Identification of oligomers at early stages of tau aggregation in
Alzheimer’s disease. FASEB J. 2012;26(5):1946–59.
[124] Pritchard SM, Dolan PJ, Vitkus A, Johnson GVW. The toxicity of tau in Alzheimer
disease: turnover, targets and potential therapeutics. J Cell Mol Med. 2011;15(8):1621–
35.
[125] Grüninger F. Invited review: drug development for tauopathies. Neuropathol Appl
Neurobiol. 2015;41(1):81–96.
[126] Collin L, Bohrmann B, Göpfert U, Oroszlan-Szovik K, Ozmen L, Grüninger F. Neuronal
uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse
model of Alzheimer’s disease. Brain. 2014;137(Pt 10):2834–46.
[127] De Strooper B, Chávez Gutiérrez L. Learning by failing: ideas and concepts to tackle
γ-secretases in Alzheimer’s disease and beyond. Annu Rev Pharmacol Toxicol.
2015;55:419–37.
[128] Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Sim‐
vastatin strongly reduces levels of Alzheimer’s disease beta -amyloid peptides Abeta
42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98(10):5856–61.
[129] Li L, Cao D, Kim H, Lester R, Fukuchi K-I. Simvastatin enhances learning and memory
independent of amyloid load in mice. Ann Neurol. 2006;60(6):729–39.
[130] Chauhan NB, Siegel GJ, Feinstein DL. Effects of lovastatin and pravastatin on amyloid
processing and inflammatory response in TgCRND8 brain. Neurochem Res.
2004;29(10):1897–911.
[131] Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer
disease: I. Review of epidemiological and preclinical studies. Arch Neurol. 2011;68(10):
1239–44.
[132] Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer
disease: II. Review of human trials and recommendations. Arch Neurol. 2011;68(11):
1385–92.
[133] Sjögren M, Gustafsson K, Syversen S, Olsson A, Edman A, Davidsson P, et al. Treatment
with simvastatin in patients with Alzheimer’s disease lowers both alpha- and beta-
cleaved amyloid precursor protein. Dement Geriatr Cogn Disord. 2003;16(1):25–30.
[134] Hoglund K, Thelen KM, Syversen S, Sjogren M, von Bergmann K, Wallin A, et al. The
effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol
Update on Dementia164
metabolism in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord.
2005;19(5–6):256–65.
[135] Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, et al. A randomized,
double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease.
Neurology. 2011;77(6):556–63.
[136] Carlsson CM, Gleason CE, Hess TM, Moreland KA, Blazel HM, Koscik RL, et al. Effects
of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults
at risk for Alzheimer’s disease. J Alzheimers Dis. 2008;13(2):187–97.
[137] Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, et al. Atorvastatin
for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch
Neurol. 2005;62(5):753–7.
[138] Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Petanceska S, et al. Atorvas‐
tatin therapy lowers circulating cholesterol but not free radical activity in advance of
identifiable clinical benefit in the treatment of mild-to-moderate AD. Curr Alzheimer
Res. 2005;2(3):343–53.
[139] Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al. Random‐
ized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.
Neurology. 2010;74(12):956–64.
[140] Jones RW, Kivipelto M, Feldman H, Sparks L, Doody R, Waters DD, et al. The Ator‐
vastatin/Donepezil in Alzheimer’s Disease Study (LEADe): design and baseline
characteristics. Alzheimers Dement. 2008;4(2):145–53.
[141] Carlsson CM, Xu G, Wen Z, Barnet JH, Blazel HM, Chappell RJ, et al. Effects of
atorvastatin on cerebral blood flow in middle-aged adults at risk for Alzheimer’s
disease: a pilot study. Curr Alzheimer Res. 2012;9(8):990–7.
[142] Friedhoff LT, Cullen EI, Geoghagen NS, Buxbaum JD. Treatment with controlled-
release lovastatin decreases serum concentrations of human beta-amyloid (A beta)
peptide. Int J Neuropsychopharmacol. 2001;4(2):127–30.
[143] Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al.
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised
controlled trial. Lancet. 2002;360(9346):1623–30.
[144] Tsuji A, Saheki A, Tamai I, Terasaki T. Transport mechanism of 3-hydroxy-3-methyl‐
glutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J Pharmacol Exp
Ther. 1993;267(3):1085–90.
[145] Carmena R,  Roederer  G,  Mailloux  H,  Lussier-Cacan S,  Davignon J.  The  response
to  lovastatin  treatment  in  patients  with  heterozygous  familial  hypercholesterole‐
mia  is  modulated  by  apolipoprotein  E  polymorphism.  Metabolism.  1993;42(7):
895–901.
Brain Lipids in the Pathophysiology and Treatment of Alzheimer’s Disease
http://dx.doi.org/10.5772/64757
165
[146] Johnson-Anuna LN, Eckert GP, Keller JH, Igbavboa U, Franke C, Fechner T, et al.
Chronic administration of statins alters multiple gene expression patterns in mouse
cerebral cortex. J Pharmacol Exp Ther. 2005;312(2):786–93.
[147] Cole SL, Grudzien A, Manhart IO, Kelly BL, Oakley H, Vassar R. Statins cause intra‐
cellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments,
and amyloid beta-peptide via an isoprenoid-dependent mechanism. J Biol Chem.
2005;280(19):18755–70.
[148] Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, et al. Beneficial
effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheim‐
ers Dement. 2010;6(6):456–64.
[149] Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G,
Garlind A, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate
Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol.
2006;63(10):1402–8.
[150] Shinto L, Quinn J, Montine T, Dodge HH, Woodward W, Baldauf-Wagner S, et al. A
randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid
in Alzheimer’s disease. J Alzheimers Dis. 2014;38(1):111–20.
[151] Jimenez S, Torres M, Vizuete M, Sanchez-Varo R, Sanchez-Mejias E, Trujillo-Estrada L,
et al. Age-dependent accumulation of soluble amyloid beta (Abeta) oligomers reverses
the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha))
by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in
Alzheimer mouse model. J Biol Chem. 2011;286(21):18414–25.
[152] Fragkouli A, Papatheodoropoulos C, Georgopoulos S, Stamatakis A, Stylianopoulou
F, Tsilibary EC, et al. Enhanced neuronal plasticity and elevated endogenous sAPPα
levels in mice over-expressing MMP9. J Neurochem. 2012;121(2):239–51.
[153] Thornton E, Vink R, Blumbergs PC, Van Den Heuvel C. Soluble amyloid precursor
protein alpha reduces neuronal injury and improves functional outcome following
diffuse traumatic brain injury in rats. Brain Res. 2006;1094(1):38–46.
[154] Lorente-Cebrián S, Costa AGV, Navas-Carretero S, Zabala M, Laiglesia LM, Martínez
JA, et al. An update on the role of omega-3 fatty acids on inflammatory and degener‐
ative diseases. J Physiol Biochem. 2015;71(2):341–9.
[155] Escribá PV. Membrane-lipid therapy: a new approach in molecular medicine. Trends
Mol Med. 2006;12(1):34–43.
[156] Escribá PV, Busquets X, Inokuchi J-I, Balogh G, Török Z, Horváth I, et al. Membrane
lipid therapy: modulation of the cell membrane composition and structure as a
molecular base for drug discovery and new disease treatment. Prog Lipid Res.
2015;59:38–53.
Update on Dementia166
[157] Nicolson GL, Ash ME. Lipid replacement therapy: a natural medicine approach to
replacing damaged lipids in cellular membranes and organelles and restoring function.
Biochim Biophys Acta. 2014;1838(6):1657–79.
[158] Ibarguren M, López DJ, Encinar JA, González-Ros JM, Busquets X, Escribá PV.
Partitioning of liquid-ordered/liquid-disordered membrane microdomains induced by
the fluidifying effect of 2-hydroxylated fatty acid derivatives. Biochim Biophys Acta.
2013;1828(11):2553–63.
[159] Fiol-Deroque MA, Gutierrez-Lanza R, Terés S, Torres M, Barceló P, Rial RV, et al.
Cognitive recovery and restoration of cell proliferation in the dentate gyrus in the
5XFAD transgenic mice model of Alzheimer’s disease following 2-hydroxy-DHA
treatment. Biogerontology. 2013;14(6):763–75.
[160] Torres M, Price SL, Fiol-Deroque MA, Marcilla-Etxenike A, Ahyayauch H, Barceló-
Coblijn G, et al. Membrane lipid modifications and therapeutic effects mediated by
hydroxydocosahexaenoic acid on Alzheimer’s disease. Biochim Biophys Acta.
2014;1838(6):1680–92.
[161] Torres M, Marcilla-Etxenike A, Fiol-deRoque MA, Escribá PV, Busquets X. The
unfolded protein response in the therapeutic effect of hydroxy-DHA against Alzheim‐
er’s disease. Apoptosis. 2015;20(5):712–24.
[162] Yang D-S, Stavrides P, Mohan PS, Kaushik S, Kumar A, Ohno M, et al. Reversal of
autophagy dysfunction in the TgCRND8 mouse model of Alzheimer’s disease ameli‐
orates amyloid pathologies and memory deficits. Brain. 2011;134(Pt 1):258–77.
[163] Schaeffer V, Lavenir I, Ozcelik S, Tolnay M, Winkler DT, Goedert M. Stimulation of
autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain.
2012;135(Pt 7):2169–77.
[164] Török Z, Crul T, Maresca B, Schütz GJ, Viana F, Dindia L, et al. Plasma membranes as
heat stress sensors: from lipid-controlled molecular switches to therapeutic applica‐
tions. Biochim Biophys Acta. 2014;1838(6):1594–618.
[165] Lopez DH, Fiol-Deroque MA, Noguera-Salvà MA, Terés S, Campana F, Piotto S, et al.
2-hydroxy arachidonic Acid: a new non-steroidal anti-inflammatory drug. PLoS One.
2013;8(8):e72052.
[166] Choi S-H, Aid S, Caracciolo L, Minami SS, Niikura T, Matsuoka Y, et al. Cyclooxyge‐
nase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse
model of Alzheimer’s disease. J Neurochem. 2013;124(1):59–68.
Brain Lipids in the Pathophysiology and Treatment of Alzheimer’s Disease
http://dx.doi.org/10.5772/64757
167

